[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"SunMed Holdings, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":344},{"warningLetters":4,"total":343},[5,32,54,77,100,124,146,168,187,205,222,238,254,271,289,305,323],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":20,"recipient_title":20,"reference_number":30,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},1621,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-02-06T14:20:00Z\">02\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-02T05:00:00Z\">02\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fehy-holdings-llc-675591-02022024\">Ehy Holdings, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Register and List\u003Cbr \u002F>\r\n","","Failure to Register and List","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>WL 2642\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jabez Liu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Ehy Holdings, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3483 Pleasant Ridge Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wingdale\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12594\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:zjksiopqiduj@wilson.ntesmail.com\"> zjksiopqiduj@wilson.ntesmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2024\u003C\u002Fp>\n\n\u003Cp>RE: WL #2642\u003C\u002Fp>\n\n\u003Cp>Dear Jabez Liu:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>:\u003C\u002Fp>\n\n\u003Cp>81799-001&nbsp; &nbsp;Nicotine Transdermal Patches\u003Cbr>\n81799-002&nbsp; &nbsp;Nicotine Transdermal Patches\u003Cbr>\n81799-003&nbsp; &nbsp;Nicotine Transdermal Patches\u003Cbr>\n81799-004&nbsp; &nbsp;Wart Remover\u003Cbr>\n81799-005&nbsp; &nbsp;Herpes Relief Cream\u003Cbr>\n81799-006&nbsp; &nbsp;Seborrheic Dermatitis and Psoriasis Cream\u003Cbr>\n81799-007&nbsp; &nbsp;Seborrheic Dermatitis and Psoriasis\u003Cbr>\n81799-008&nbsp; &nbsp;Nupharmisto Tattoo Numbing Cream\u003Cbr>\n81799-009&nbsp; &nbsp;Shingles Pain Relief Cream\u003Cbr>\n81799-010&nbsp; &nbsp;Nupharmisto Psoriasis Eczema Cream\u003C\u002Fp>\n\n\u003Cp>Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, these drugs are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. The listing file for drug listings must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&amp;C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the aforementioned drug listings, the manufacturer referenced is identified as Ehy Holdings, LLC (DUNS 117322715). After review of your June 27, 2023 communication with FDA’s Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ), it was revealed that Ehy Holdings, LLC is not currently involved in the manufacturing processes of drugs that are being distributed in U.S. commercial distribution nor imported or offered for import into the United States and therefore, should not be registered as a manufacturer. Consequently, the listings for these drug products are not referencing a correct or active registered manufacturing establishment and no listing updates have been provided.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\n\n\u003Cp>In addition, Nicotine Transdermal Patches (NDC 81799-001), Nicotine Transdermal Patches (NDC 81799-002), Nicotine Transdermal Patches (NDC 81799-003), Wart Remover (NDC 81799-004), Herpes Relief Cream (NDC 81799-005), Seborrheic Dermatitis and Psoriasis Cream (NDC 81799-006), Seborrheic Dermatitis and Psoriasis (NDC 81799-007), Nupharmisto Tattoo Numbing Cream (NDC 81799-008), Shingles Pain Relief Cream (NDC 81799-009), and Nupharmisto Psoriasis Eczema Cream (NDC 81799-010) are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2642 on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith, Director\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>CC: orapharm1opdiv1mgmt@fda.hhs.gov\u003Cbr>\nAttn: Director of Compliance\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>On December 1, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 15, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Reference #:\n\nWL 2642\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJabez Liu\n\nEhy Holdings, LLC\n\n3483 Pleasant Ridge Road\n\nWingdale, NY 12594\n\nUnited States\n\nzjksiopqiduj@wilson.ntesmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2024\n\nRE: WL #2642\n\nDear Jabez Liu:\n\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products1:\n\n81799-001 Nicotine Transdermal Patches\n\n81799-002 Nicotine Transdermal Patches\n\n81799-003 Nicotine Transdermal Patches\n\n81799-004 Wart Remover\n\n81799-005 Herpes Relief Cream\n\n81799-006 Seborrheic Dermatitis and Psoriasis Cream\n\n81799-007 Seborrheic Dermatitis and Psoriasis\n\n81799-008 Nupharmisto Tattoo Numbing Cream\n\n81799-009 Shingles Pain Relief Cream\n\n81799-010 Nupharmisto Psoriasis Eczema Cream\n\nYour firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&C Act), 21 U.S.C 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, these drugs are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C 352(o). Introduction or delivery for introduction of such misbranded drug(s) into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C 331(a). These violations are described in more detail below.\n\nRegistration and Drug Listing Violations\n\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. The listing file for drug listings must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the aforementioned drug listings, the manufacturer referenced is identified as Ehy Holdings, LLC (DUNS 117322715). After review of your June 27, 2023 communication with FDA’s Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ), it was revealed that Ehy Holdings, LLC is not currently involved in the manufacturing processes of drugs that are being distributed in U.S. commercial distribution nor imported or offered for import into the United States and therefore, should not be registered as a manufacturer. Consequently, the listings for these drug products are not referencing a correct or active registered manufacturing establishment and no listing updates have been provided.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\n\nIn addition, Nicotine Transdermal Patches (NDC 81799-001), Nicotine Transdermal Patches (NDC 81799-002), Nicotine Transdermal Patches (NDC 81799-003), Wart Remover (NDC 81799-004), Herpes Relief Cream (NDC 81799-005), Seborrheic Dermatitis and Psoriasis Cream (NDC 81799-006), Seborrheic Dermatitis and Psoriasis (NDC 81799-007), Nupharmisto Tattoo Numbing Cream (NDC 81799-008), Shingles Pain Relief Cream (NDC 81799-009), and Nupharmisto Psoriasis Eczema Cream (NDC 81799-010) are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2642 on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith, Director\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nCC: orapharm1opdiv1mgmt@fda.hhs.gov\n\nAttn: Director of Compliance\n\n_________________________\n\n1On December 1, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 15, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).","Ehy Holdings, LLC","ehy-holdings-llc-675591-02022024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fehy-holdings-llc-675591-02022024","2026-10-26T08:08:31.724605+00:00","Warning Letter","Issued","2024-02-06","675591","Drugs","Jabez Liu","2026-08-20T00:19:09.056+00:00","WL 2642","2024-02-02",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":20,"reference_number":20,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},2464,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-09-06T13:20:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-26T04:00:00Z\">08\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuuv-holdings-inc-640705-08262022\">MUUV Holdings Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael T. Banta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>MUUV Holdings Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>43 Rainey St. Apt 2605\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78701-4450\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@muuvpouches.com\"> info@muuvpouches.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 26, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Michael T. Banta:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fmuuvpouches.com and determined that the nicotine pouch products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the websitehttps:\u002F\u002Fmuuvpouches.com revealed that you manufacture and offer for sale or distribution to customers in the United States nicotine pouch products without a marketing authorization order, including: Wintergreen, Mint, and Citrus nicotine pouches.\u003C\u002Fp>\n\n\u003Cp>The nicotine pouch products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201844, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Mallory Johnson at (240) 402- 4709 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Contact Privacy Inc. Customer 0161932284\u003Cbr>\nMuuvpouches.com@contactprivacy.com\u003C\u002Fp>\n\n\u003Cp>Tucows Domains, Inc.\u003Cbr>\ndomainabuse@tucows.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMichael T. Banta\n\nMUUV Holdings Inc.\n\n43 Rainey St. Apt 2605\n\nAustin, TX 78701-4450\n\nUnited States\n\ninfo@muuvpouches.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 26, 2022\n\nWARNING LETTER\n\nDear Michael T. Banta:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fmuuvpouches.com and determined that the nicotine pouch products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and are intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. §387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the websitehttps:\u002F\u002Fmuuvpouches.com revealed that you manufacture and offer for sale or distribution to customers in the United States nicotine pouch products without a marketing authorization order, including: Wintergreen, Mint, and Citrus nicotine pouches.\n\nThe nicotine pouch products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201844, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Mallory Johnson at (240) 402- 4709 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nContact Privacy Inc. Customer 0161932284\n\nMuuvpouches.com@contactprivacy.com\n\nTucows Domains, Inc.\n\ndomainabuse@tucows.com\n\nShopify, Inc.\n\nabuse@shopify.com","MUUV Holdings Inc.","muuv-holdings-inc-640705-08262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmuuv-holdings-inc-640705-08262022","2026-10-26T08:09:28.804465+00:00","2022-09-06","640705","Tobacco","Michael T. Banta","2026-08-20T01:37:01.606+00:00","VIA UPS and Electronic Mail","2022-08-26",{"id":55,"raw":56,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":24,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":20,"issuing_office":60,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":20,"reference_number":20,"action_taken_date":76,"medical_device_id":20,"response_letter_date":20},1162,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-18T05:00:00Z\">11\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstew-leonards-holdings-llc-681214-11182024\">Stew Leonard’s Holdings LLC\u003C\u002Fa>","Human Foods Program","Food Labeling\u002FMisbranded\u003Cbr \u002F>\r\n","Food Labeling\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Stew Leonard, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stew Leonard’s Holdings LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>100 Westport Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Norwalk\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06851-3915\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 18, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref: CMS Case #681214\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Leonard:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 99 Federal Rd., Danbury, CT from January 26, 2024 to February 12, 2024. Based on inspectional findings and review of the product labels collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>On January 23, 2024, after being notified of a consumer complaint received by the FDA regarding an anaphylactic death associated with Stew Leonard’s brand Florentine Cookies, your firm recalled the cookies. The products contained peanuts and eggs but your printed label on the package did not contain an allergen statement or ingredient declaration for peanuts or eggs.\u003C\u002Fp>\n\n\u003Cp>1. Your Florentine Cookies products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels fail to declare the major food allergens, peanuts and egg, as required by section 403(w)(1) of the Act. Specifically, your Florentine Cookies products are manufactured for you using peanuts and eggs as ingredients, but these ingredients are not listed on the finished product label.\u003C\u002Fp>\n\n\u003Cp>Section 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils, as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Whey (Milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. Your Florentine Cookies and Rainbow Cookies products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients, and the common or usual name of each ingredient is not declared on the label, as required under 21 CFR 101.4. Specifically,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The Florentine Cookies product is manufactured with the following ingredients that are not declared on your finished product label: peanuts, eggs, margarine (and its sub-ingredients), citric acid, mixed tocopherols, and palm kernel oil.\u003C\u002Fli>\n\t\u003Cli>The Rainbow Cookies product is manufactured with the following ingredients that are not declared on your finished product label: Rice Flour, Apricot Kernels, Raspberries, Baking Powder (Sodium Acid Pyrophosphate, Baking Soda, Corn Starch, Monocalcium Phosphate), Wheat Gluten, Potassium Sorbate Preservative, Calcium Citrate, Fruit Juice Color, Vegetable Juice Color, Sodium Lauryl Sulfate, Calcium Chloride, Carnauba Wax, and Xanthan Gum. Further, we note that your finished product label does not appear to have been updated after changing cookie suppliers.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient [21 CFR 101.4(b)(2)(i)], or by listing the component ingredients without listing the ingredient itself [21 CFR 101.4(b)(2)(ii)]. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\u003C\u002Fp>\n\n\u003Cp>3. Your Rainbow Cookies product is misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] because the Nutrition Facts label (NFL) is not in accordance with 21 CFR 101.9. Specifically, the NFL is not in the correct format. For example:\u003Cbr>\n&nbsp; &nbsp; a. The calorie declaration is not shown bolded and in larger print size, as required by 21 CFR 101.9(d)(1)(iii).\u003Cbr>\n&nbsp; &nbsp; b. It lacks the declaration for added sugars, as required by 21 CFR 101.9(c)(6)(iii)\u003Cbr>\n&nbsp; &nbsp; c. It lacks the declaration for the required vitamins and minerals, vitamin D and potassium, as required by 21 CFR 101.9(c)(8)(ii)\u003Cbr>\n&nbsp; &nbsp; d. The footnote is not as required by 21 CFR 101.9(d)(9).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of the violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, or injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your Florentine Cookies product lists “Sodium Benzoate” and “Soy Nuts” as ingredients which are not present on the ingredient list of the bulk cookies you receive. We note that your product label must accurately reflect the ingredients used to make this cookie. If the sodium benzoate ingredient performs a preservative function in this product, the function of the preservative must be declared to be in compliance with 21 CFR 101.22(j).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify FDA in writing within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time frame within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration via email to HFP-OCE-Labeling@fda.hhs.gov. If sending a response by mail, address to Food and Drug Administration Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Critical Foods and Dietary Supplement Enforcement HFS-608, 5001 Campus Drive, College Park, MD 20740.If you have any questions regarding any issues in this letter, please contact HFP-OCE-Labeling@fda.hhs.gov and include reference #681214 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>\nActing Director, Office of Enforcement\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nHuman Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nStew Leonard, Jr.\n\nRecipient Title\n\nCEO\n\nStew Leonard’s Holdings LLC\n\n100 Westport Ave\n\nNorwalk, CT 06851-3915\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nNovember 18, 2024\n\nWARNING LETTER\n\nRef: CMS Case #681214\n\nDear Mr. Leonard:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 99 Federal Rd., Danbury, CT from January 26, 2024 to February 12, 2024. Based on inspectional findings and review of the product labels collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nOn January 23, 2024, after being notified of a consumer complaint received by the FDA regarding an anaphylactic death associated with Stew Leonard’s brand Florentine Cookies, your firm recalled the cookies. The products contained peanuts and eggs but your printed label on the package did not contain an allergen statement or ingredient declaration for peanuts or eggs.\n\n1. Your Florentine Cookies products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels fail to declare the major food allergens, peanuts and egg, as required by section 403(w)(1) of the Act. Specifically, your Florentine Cookies products are manufactured for you using peanuts and eggs as ingredients, but these ingredients are not listed on the finished product label.\n\nSection 201(qq) of the Act [21 U.S.C. § 321(qq)], defines milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, soybeans, and sesame, as well as any food ingredient that contains protein derived from one of these foods, with the exception of highly refined oils, as “major food allergens.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Whey (Milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n\n2. Your Florentine Cookies and Rainbow Cookies products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients, and the common or usual name of each ingredient is not declared on the label, as required under 21 CFR 101.4. Specifically,\n\nThe Florentine Cookies product is manufactured with the following ingredients that are not declared on your finished product label: peanuts, eggs, margarine (and its sub-ingredients), citric acid, mixed tocopherols, and palm kernel oil.\n\nThe Rainbow Cookies product is manufactured with the following ingredients that are not declared on your finished product label: Rice Flour, Apricot Kernels, Raspberries, Baking Powder (Sodium Acid Pyrophosphate, Baking Soda, Corn Starch, Monocalcium Phosphate), Wheat Gluten, Potassium Sorbate Preservative, Calcium Citrate, Fruit Juice Color, Vegetable Juice Color, Sodium Lauryl Sulfate, Calcium Chloride, Carnauba Wax, and Xanthan Gum. Further, we note that your finished product label does not appear to have been updated after changing cookie suppliers.\n\nAccording to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient [21 CFR 101.4(b)(2)(i)], or by listing the component ingredients without listing the ingredient itself [21 CFR 101.4(b)(2)(ii)]. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\n\n3. Your Rainbow Cookies product is misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] because the Nutrition Facts label (NFL) is not in accordance with 21 CFR 101.9. Specifically, the NFL is not in the correct format. For example:\n\na. The calorie declaration is not shown bolded and in larger print size, as required by 21 CFR 101.9(d)(1)(iii).\n\nb. It lacks the declaration for added sugars, as required by 21 CFR 101.9(c)(6)(iii)\n\nc. It lacks the declaration for the required vitamins and minerals, vitamin D and potassium, as required by 21 CFR 101.9(c)(8)(ii)\n\nd. The footnote is not as required by 21 CFR 101.9(d)(9).\n\nThis letter is not intended to be an all-inclusive list of the violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, or injunction.\n\nWe also have the following comment:\n\nYour Florentine Cookies product lists “Sodium Benzoate” and “Soy Nuts” as ingredients which are not present on the ingredient list of the bulk cookies you receive. We note that your product label must accurately reflect the ingredients used to make this cookie. If the sodium benzoate ingredient performs a preservative function in this product, the function of the preservative must be declared to be in compliance with 21 CFR 101.22(j).\n\nPlease notify FDA in writing within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time frame within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration via email to HFP-OCE-Labeling@fda.hhs.gov. If sending a response by mail, address to Food and Drug Administration Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Critical Foods and Dietary Supplement Enforcement HFS-608, 5001 Campus Drive, College Park, MD 20740.If you have any questions regarding any issues in this letter, please contact HFP-OCE-Labeling@fda.hhs.gov and include reference #681214 on any submissions and within the subject line of any email correspondence to the agency.\n\nSincerely,\n\n\u002FS\u002F\n\nMaria S. Knirk, JD MBA\n\nActing Director, Office of Enforcement\n\nOffice of Compliance and Enforcement\n\nHuman Foods Program","Stew Leonard’s Holdings LLC","stew-leonards-holdings-llc-681214-11182024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstew-leonards-holdings-llc-681214-11182024","2026-10-26T08:10:06.031762+00:00","2024-11-26","681214","Food & Beverages","Stew Leonard, Jr.","2026-08-19T18:13:57.799+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-11-18",{"id":78,"raw":79,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":90,"fei_number":20,"letter_url":91,"updated_at":92,"action_type":23,"case_status":24,"posted_date":93,"marcs_cms_no":94,"product_type":95,"closeout_date":20,"issuing_office":83,"recipient_name":96,"body_fetched_at":97,"delivery_method":75,"recipient_title":20,"reference_number":98,"action_taken_date":99,"medical_device_id":20,"response_letter_date":20},899,[80,81,82,83,84,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-16T05:00:00Z\">12\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskye-biologics-holdings-llc-654466-12162024\">Skye Biologics Holdings LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)\u003Cbr \u002F>\r\n","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-654466\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher M.B. Sharp\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Skye Biologics Holdings LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2255 Campus Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Segundo\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90245-0001\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CBER-24-654466&nbsp;\u003C\u002Fp>\u003Cp>December 16, 2024&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Sharp:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at 2255 Campus Dr, El Segundo, CA 90245, between November 29, 2022 and December 9, 2022. During the inspection, FDA documented that your company manufactures “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioECM™ (collectively, “your products\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>”).&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your introduction or delivery for introduction of your product[s] into interstatecommerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act,21 U.S.C. § 331(d). Your products are also unlicensed biological products in violation of section 351(a) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your adulterated products into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA prior to, during, and\u002For after the inspection, including information on your website, www.skyebiologics.com, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your webpage for “Tissue Transplants Utilizing Extracellular Matrix Preservation (BioECM) Technology”, located at https:\u002F\u002Fwww.skyebiologics.com\u002Ftechnology, states that “Not all Placental Allografts are Created Equal… Placental tissues have been shown in the literature to be naturally anti-inflammatory, anti-fibrotic, anti-microbial, to modulate inflammation, promote tissue remodeling and reduce scar tissue formation in clinical applications.”\u003C\u002Fli>\u003Cli>In a press release regarding your BioECM product, you state that “FastActing Amniotic Membranes are part of HRT’s &amp; Skye’s extensive line of amniotic and placental products designed to help support proper tissue remodeling while modulating scarring and inflammation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including, as applicable, premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form, drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended solely to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your products are intended for, e.g., modulation of inflammation and promotion of remodeling of tissues; anti-inflammatory, anti-fibrotic, and anti-microbial purposes; and supplementing or filling a void, which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, these products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant violations from CGMP requirements, including violations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR parts 210 and 211.\u003C\u002Fp>\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant violations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the November 2022 inspection, as discussed below.\u003C\u002Fp>\u003Cp>The CGMP violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. 21 CFR 211.100(a).\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for your products with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area, 21 CFR 211.42(c)(10)(iv), as well as failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 21 CFR 211.113(b).\u003C\u002Fstrong> Your written procedures for environmental monitoring of your firm’s aseptic processing areas (e.g., laminar flow hoods) are not sufficient to detect problems and ensure low bioburden levels prior to sterilization. For example,\u003C\u002Fp>\u003Cp>a. You do not perform nonviable particulate monitoring or viable microbial \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring within your ISO 5 laminar flow hoods in association with all production shifts. You also do not conduct personnel monitoring of operators who perform processing of your products. Due to the higher risk of microbial contamination in this environment where open processing occurs, environmental monitoring inside the laminar flow hood should be conducted in association with each batch.\u003C\u002Fp>\u003Cp>b. Your ISO 5 laminar flow hoods, which are used for tissue cleaning, rinsing, and weighing, are located within an unclassified area. The area immediately adjacent to the critical processing areas should be controlled and monitored to minimize the level of potential contaminants in the final product.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure the components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality and purity. 21 CFR211.160(b).\u003C\u002Fstrong> For example, you have not established appropriate specifications to assure that your products conform to appropriate standards of identity, strength, &nbsp;quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.21 CFR 211.165(b).\u003C\u002Fstrong> Specifically, you failed to perform endotoxin testing on final product batches. Such laboratory testing is necessary as your products are purported to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192. \u003C\u002Fstrong>For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b).\u003C\u002Fstrong> Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps, for example:\u003C\u002Fp>\u003Cp>a. The weight of, for e.g., umbilical cord tissue used in processing.\u003C\u002Fp>\u003Cp>b. The amount of saline used to formulate the final product.\u003C\u002Fp>\u003Cp>c. Processing of tissue in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, including weight of tissue processed, machine operational parameters, run time, and the number of runs completed.\u003C\u002Fp>\u003Cp>d. Identification of equipment, such as laminar flow hoods, used in processing.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates. 21 CFR 211.166(a).\u003C\u002Fstrong> Specifically, your firm has assigned a five-year expiration date for your products without supporting data regarding the stability characteristics of the products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your letter received on January 3, 2023, which provides a response to FDA’s inspectional observations (FDA-483). We have reviewed the represented corrective actions outlined in the response, and these actions are not adequate to address the above-noted violations. For example, your response does not address your firm’s continued manufacture and distribution of your products or your plans for disposition of your current inventory manufactured under the violative conditions outlined above.\u003C\u002Fp>\u003Cp>Your firm’s response repeatedly asserts that your products should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your products. Based on your position, you have not proposed corrective actions which address the CGMP violations noted above. While you assert that your products should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your products do not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\u003C\u002Fp>\u003Cp>As such, your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we have concerns with your “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioRenew™, and products derived from amniotic and chorionic membrane and umbilical cord, namely HRT® BioPower-A, HRT® BioPower-C, and HRT® NX. In your response, please explain the basis for your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.&nbsp;\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.&nbsp;\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.&nbsp;\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent any violations, or similar violations, from occurring again. Include any documentation necessary to show that these matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market your BioECM™ products as BioECM ActiveMatrix®, BioECM BurnMatrix®, BioECM CryoMatrix®, BioECM MX™, BioECM NX™, BioECM RX, BioECM WoundEx™.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all of the other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER-24-654466\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nChristopher M.B. Sharp\n\nRecipient Title\n\nChief Executive Officer\n\nSkye Biologics Holdings LLC\n\n2255 Campus Dr\n\nEl Segundo, CA 90245-0001\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nCBER-24-654466\nDecember 16, 2024\nDear Mr. Sharp:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at 2255 Campus Dr, El Segundo, CA 90245, between November 29, 2022 and December 9, 2022. During the inspection, FDA documented that your company manufactures “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioECM™ (collectively, “your products1”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your introduction or delivery for introduction of your product[s] into interstatecommerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act,21 U.S.C. § 331(d). Your products are also unlicensed biological products in violation of section 351(a) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your adulterated products into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA prior to, during, and\u002For after the inspection, including information on your website, www.skyebiologics.com, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour webpage for “Tissue Transplants Utilizing Extracellular Matrix Preservation (BioECM) Technology”, located at https:\u002F\u002Fwww.skyebiologics.com\u002Ftechnology, states that “Not all Placental Allografts are Created Equal… Placental tissues have been shown in the literature to be naturally anti-inflammatory, anti-fibrotic, anti-microbial, to modulate inflammation, promote tissue remodeling and reduce scar tissue formation in clinical applications.”\nIn a press release regarding your BioECM product, you state that “FastActing Amniotic Membranes are part of HRT’s & Skye’s extensive line of amniotic and placental products designed to help support proper tissue remodeling while modulating scarring and inflammation.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including, as applicable, premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form, drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended solely to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your products are intended for, e.g., modulation of inflammation and promotion of remodeling of tissues; anti-inflammatory, anti-fibrotic, and anti-microbial purposes; and supplementing or filling a void, which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, these products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nAdditionally, during the inspection, FDA investigators documented evidence of significant violations from CGMP requirements, including violations from section 501(a)(2)(B) of the FD&C Act and 21 CFR parts 210 and 211.\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant violations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the November 2022 inspection, as discussed below.\nThe CGMP violations include, but are not limited to, the following:\n1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. 21 CFR 211.100(a). Specifically, your firm has not validated the manufacturing processes for your products with respect to identity, strength, quality, and purity.\n2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area, 21 CFR 211.42(c)(10)(iv), as well as failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 21 CFR 211.113(b). Your written procedures for environmental monitoring of your firm’s aseptic processing areas (e.g., laminar flow hoods) are not sufficient to detect problems and ensure low bioburden levels prior to sterilization. For example,\na. You do not perform nonviable particulate monitoring or viable microbial (b)(4) monitoring within your ISO 5 laminar flow hoods in association with all production shifts. You also do not conduct personnel monitoring of operators who perform processing of your products. Due to the higher risk of microbial contamination in this environment where open processing occurs, environmental monitoring inside the laminar flow hood should be conducted in association with each batch.\nb. Your ISO 5 laminar flow hoods, which are used for tissue cleaning, rinsing, and weighing, are located within an unclassified area. The area immediately adjacent to the critical processing areas should be controlled and monitored to minimize the level of potential contaminants in the final product.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure the components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality and purity. 21 CFR211.160(b). For example, you have not established appropriate specifications to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n4. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.21 CFR 211.165(b). Specifically, you failed to perform endotoxin testing on final product batches. Such laboratory testing is necessary as your products are purported to be sterile.\n5. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192. For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).\n6. Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b). Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps, for example:\na. The weight of, for e.g., umbilical cord tissue used in processing.\nb. The amount of saline used to formulate the final product.\nc. Processing of tissue in the (b)(4) machine, including weight of tissue processed, machine operational parameters, run time, and the number of runs completed.\nd. Identification of equipment, such as laminar flow hoods, used in processing.\n7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates. 21 CFR 211.166(a). Specifically, your firm has assigned a five-year expiration date for your products without supporting data regarding the stability characteristics of the products.\nResponse to the Form FDA-483\nWe acknowledge receipt of your letter received on January 3, 2023, which provides a response to FDA’s inspectional observations (FDA-483). We have reviewed the represented corrective actions outlined in the response, and these actions are not adequate to address the above-noted violations. For example, your response does not address your firm’s continued manufacture and distribution of your products or your plans for disposition of your current inventory manufactured under the violative conditions outlined above.\nYour firm’s response repeatedly asserts that your products should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your products. Based on your position, you have not proposed corrective actions which address the CGMP violations noted above. While you assert that your products should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your products do not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\nAs such, your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\nAdditional Concerns\nIn addition, we have concerns with your “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioRenew™, and products derived from amniotic and chorionic membrane and umbilical cord, namely HRT® BioPower-A, HRT® BioPower-C, and HRT® NX. In your response, please explain the basis for your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent any violations, or similar violations, from occurring again. Include any documentation necessary to show that these matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 You market your BioECM™ products as BioECM ActiveMatrix®, BioECM BurnMatrix®, BioECM CryoMatrix®, BioECM MX™, BioECM NX™, BioECM RX, BioECM WoundEx™.\n2 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all of the other criteria in 21 CFR 1271.10(a).","Skye Biologics Holdings LLC","skye-biologics-holdings-llc-654466-12162024","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskye-biologics-holdings-llc-654466-12162024","2026-10-26T08:09:58.907333+00:00","2025-05-20","654466","Biologics","Christopher M.B. Sharp","2026-08-19T16:46:38.883+00:00","CBER-24-654466","2024-12-16",{"id":101,"raw":102,"subject":107,"body_html":109,"body_text":110,"firm_name":111,"letter_id":112,"created_at":90,"fei_number":20,"letter_url":113,"updated_at":114,"action_type":23,"case_status":115,"posted_date":116,"marcs_cms_no":117,"product_type":118,"closeout_date":119,"issuing_office":106,"recipient_name":120,"body_fetched_at":121,"delivery_method":122,"recipient_title":20,"reference_number":20,"action_taken_date":123,"medical_device_id":20,"response_letter_date":20},787,[103,104,105,106,107,13,108,13],"\u003Ctime datetime=\"2025-07-08T04:00:00Z\">07\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-12T04:00:00Z\">06\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjd-heiskell-holdings-llc-700893-06122025\">J.D. Heiskell Holdings LLC\u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FFood for Animals\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-d-heiskell-holdings-llc-700893-03202026\">\u003Ctime datetime=\"2026-03-27T04:00:00Z\">03\u002F27\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bradley R. More\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Plant Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>J.D. Heiskell Holdings LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2407 Warren Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Twin Falls\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83301-7978\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 700893\u003C\u002Fp>\u003Cp>June 12, 2025\u003C\u002Fp>\u003Cp>Dear Bradley More,\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your unlicensed feed mill that manufactures both medicated and non-medicated animal food, located at 2407 Warren Avenue, Twin Falls, Idaho, from December 2 to 5, 2024. The inspection was initiated in response to a Reportable Food Registry (RFR) report your firm filed on November 11, 2024, after receiving a consumer complaint on October 20, 2024, reporting multiple deaths of calves after consuming your Bliss Calf Starter medicated feed product. Your third-party lab analyzed samples of feed from the customer and reported the presence of excessive monensin in one lot of Bliss Calf Starter. You initiated a voluntary Class I recall of this medicated feed due to excessive monensin on October 21, 2024. We received and evaluated your written response to the Form FDA 483, Inspectional Observations, (FDA 483) dated December 9, 2024.\u003C\u002Fp>\u003Cp>During the inspection, the FDA investigator found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements found in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which causes your products to be adulterated because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR Part 507 is prohibited.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In addition, the FDA investigator found evidence that you manufactured and distributed Bliss Calf Starter medicated feed that contained a super-potent concentration of the new animal drug monensin. This Type C medicated cattle feed containing the Type A medicated article of monensin is unsafe because the new animal drug was not used in conformance with the drug approval because the quantity in the final feed exceeded the approved safe level for use in cattle feed.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As a result, the Bliss Calf Starter medicated feed containing the new animal drug is adulterated.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Further, the inspection revealed evidence of significant violations of Current Good Manufacturing Practice (CGMP) for Medicated Feeds, 21 CFR Part 225. Failure of your medicated feed mill to comply with these requirements also causes your medicated and non-medicated feeds to be adulterated.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Additionally, your Bliss Calf Starter feed is misbranded because its labeling does not bear adequate directions for use.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described further below, you attempted to recondition the Bliss Calf Starter medicated feed containing a super-potent concentration of monensin by mixing the feed into your non-medicated Dry Creek High Cow formulation. Therefore, your Dry Creek High Cow feed is also misbranded because its label does not bear the name and quantity of each active ingredient.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the article being adulterated or misbranded is prohibited.\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Furthermore, you failed to report a reportable food to the RFR within twenty-four hours of determining that it is a reportable food (i.e., an animal food for which there is a reasonable probability that the use of, or exposure to, such animal food will cause serious adverse health consequences or death to animals).\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Failure to submit a required reportable food report is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>10\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You may find the FD&amp;C Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>At the close of the inspection, you were issued an FDA 483. As noted above, we received your written response dated December 9, 2024. We have reviewed your response and address your corrective actions below in relation to each of the noted violations.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA investigator observed evidence of significant violations of these requirements, which included the following:\u003C\u002Fp>\u003Cp>1. You failed to sufficiently assess the probability that a hazard will occur in the absence of preventive controls, as required by 21 CFR 507.33(c)(1).\u003C\u002Fp>\u003Cp>a. Your hazard analysis identified that excess animal drug due to “weighing error” is a known or reasonably foreseeable hazard, and you determined that a preventive control was not required due to your prerequisite program. Specifically, your hazard analysis indicates that you will control the hazard at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step through the use of “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Procedure” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification prerequisite programs.\u003C\u002Fp>\u003Cp>However, your prerequisite program was not implemented in a way that reduces the probability of occurrence of the hazard, as evidenced by the excessive monensin in batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your Bliss Calf Starter medicated feed. On October 13, 2024, your employee added 169.6 lbs. of monensin to this batch of Bliss Calf Starter medicated feed, which exceeds the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs. of monensin that is called for in this formulation of feed and resulted in a calculated super-potent concentration of 476 g\u002Fton in the finished calf feed. After a customer notified you of calf deaths after consuming the Bliss Calf Starter medicated feed, your facility collected and submitted samples of the feed to a third-party laboratory, which found that it contained 276 g\u002Fton of monensin. Therefore, you did not reduce the probability that the excess animal drug hazard would occur in the absence of a preventive control.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>During the inspection and in your written response dated December 9, 2024, you stated that you made corrections including verifying the drug log and monitoring the accuracy of \u003Cstrong>(b)(4)\u003C\u002Fstrong> adds \u003Cstrong>(b)(4)\u003C\u002Fstrong> and amending your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> SOP 208” procedure for drug quantities to be entered into your electronic usage report. However, we are unable to fully evaluate your corrective actions since you did not provide supporting documentation to demonstrate that these corrections have been implemented or that employees have been trained regarding the updated procedure. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>b. Your hazard analysis identified at the “Rework &amp; Returned Material” manufacturing step that you are controlling the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” hazard using your “Rework Plan” as a prerequisite program. However, you stated during the inspection that you did not have a rework written procedure. If you rely on a prerequisite program in your evaluation of the probability of occurrence of a hazard, adequate information about the prerequisite program must be included in your hazard analysis as part of your evaluation.\u003C\u002Fp>\u003Cp>Furthermore, despite your claimed prerequisite program, you mixed the recalled Bliss Calf Starter medicated feed containing monensin with a non-medicated customer-formula animal food to produce a reworked product labeled Dry Creek High Cow which you estimated contained 9.66 g\u002Fton of monensin. The Dry Creek High Cow food was not labeled to contain monensin. Therefore, your prerequisite program does not reduce the probability of the hazard of medication in a non-medicated animal food in the absence of a preventive control.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>Your written response to the FDA 483 stated that you intend to establish a written standard operating procedure for reconditioning feed within the next 90 days, which will include a written rework plan and records that accurately document how feed is reconditioned. To date, we have not received a copy of the procedure or records to demonstrate your corrections have been implemented. Therefore, we are unable to fully evaluate your corrective actions. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>c. Your reliance on prerequisite programs failed to reduce the probability that mycotoxins would occur in your animal food ingredients in the absence of a preventive control. Your hazard analysis identified mycotoxins, under “Natural toxins,” as a potential hazard for animal food ingredients including corn, soybeans, and wheat, and indicates that you will control the hazard with your preferred supplier program and “Quality Sample Schedule” prerequisite programs. However, our investigator found no evidence that you are following your prerequisite programs. For example, your sampling procedure states that each commodity will be tested for mycotoxins \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You were unable to provide any records to demonstrate that any of the ingredients susceptible to mycotoxins were sampled and analyzed for the presence of mycotoxins since March 2023.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>Your response dated December 9, 2024, stated that your “Quality Sampling Schedule” procedure was not reflective of the actual sampling conducted at your establishment and that you will begin testing each commodity for mycotoxins \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide any documentation to demonstrate the implementation of your corrective actions. Furthermore, you did not provide any justification that \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis per commodity will be sufficient to control mycotoxins in the grain ingredients you use to manufacture animal food. Therefore, we are unable to fully evaluate the corrections you have made. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medicated Feed Current Good Manufacturing Practice Requirements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your facility is required to follow the medicated feed CGMP regulations for non-licensed, medicated animal feed manufacturers found in 21 CFR 225.120-202. During the inspection, the FDA investigator observed evidence of violations of these requirements, which included:\u003C\u002Fp>\u003Cp>2. You did not establish and maintain adequate procedures for the identification, storage, and inventory control (receipt and use) of all Type A medicated articles and Type B medicated feeds intended for use in the manufacture of medicated feed to aid in assuring the identity, strength, quality, and purity of these drug sources. All Type A medicated articles and Type B medicated feeds must be used in accordance with their labeled mixing directions, as required by 21 CFR 225.142. Specifically:\u003C\u002Fp>\u003Cp>a. While your formula for Bliss Calf Starter medicated feed called for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbs. of monensin (consistent with the labeled mixing directions), your records show that on October 13, 2024, your employee added 169.6 lbs. of monensin to batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your Bliss Calf Starter medicated feed.\u003C\u002Fp>\u003Cp>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> SOP 208” was not adequate because it did not prevent the weighing error that resulted in a super-potent medicated feed that contained excessive monensin. Furthermore, you had no documentation that your drug log or batch records were verified by anyone for accuracy (theoretical usage based on formula versus actual medicated article pulled from inventory) prior to the distribution of your Bliss Calf Starter medicated feed, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. During the inspection, you provided a reconditioning proposal, dated November 15, 2024, which documented your plan to manufacture Dry Creek High Cow animal food that is intended to be non-medicated. The proposal shows that the Dry Creek High Cow food would be combined with the recalled super-potent Bliss Calf Starter medicated feed, which you manufactured from the Type A medicated article monensin. This proposal does not document procedures for reworking medicated feed in a way that aids in assuring that Type A drug components maintain the identity, strength, quality, and purity throughout manufacturing at your facility and so that Type A medicated articles and Type B medicated feeds are used in accordance with their labeled mixing directions. Additionally, while you explained to the FDA investigator that the Dry Creek High Cow feed was manufactured in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, this is not reflected in the reconditioning proposal.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>In your written response dated December 9, 2024, you stated that your corrections included verifying the accuracy of the drug log \u003Cstrong>(b)(4)\u003C\u002Fstrong> and amending your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> SOP 208” procedure for drug quantities to be entered into your electronic usage report. You also stated that you intend to create a rework procedure and implementation records. However, your response did not include supporting documentation to demonstrate that these corrections have been implemented or that employees have been trained regarding the updated procedure. Therefore, we are unable to fully evaluate your corrections. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\u003C\u002Fp>\u003Cp>3. You failed to ensure that all deliveries of medicated feeds, whether bagged or in bulk, are adequately labeled to assure that the feed can properly be used, as required by 21 CFR 225.180.\u003Cem>\u003Cstrong>\u003Csup>11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Specifically, your Type C Bliss Calf Starter medicated feed label did not include adequate feeding directions set forth in the new animal drug approval for monensin-medicated cattle feed for the labeled monensin concentration of 60.9 g\u002Fton, nor indications for use. Your label states, “Feed as directed by nutritionist.” We note that feeding directions and indications for use are sections included in the representative (“\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) labeling for monensin-medicated cattle feed.\u003Cem>\u003Cstrong>\u003Csup>12\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>In your written response dated December 9, 2024, you stated you intend to verify and update the necessary feed labels. However, you have not provided updated feed labels to demonstrate your corrections have been implemented. We are, therefore, unable to fully evaluate the corrections you have made.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Attempted Reconditioning of Adulterated Animal Food\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your reconditioning proposal, you documented that you attempted to recondition the Bliss Calf Starter feed, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which contained a super-potent concentration of monensin (the “super-potent” feed), by mixing the super-potent feed with your standard-formulated Bliss Calf Starter feed, containing 60 g\u002Fton monensin, to create an unspecified lot of Blended Bliss Calf Starter feed containing a calculated 154.6316 g\u002Fton of monensin. You then mixed the Blended Bliss Calf Starter feed with non-medicated Dry Creek High Cow food to create at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots containing a calculated 9.6644 g\u002Fton of monensin. You labeled the finished product as Dry Creek High Cow, and its labeling did not declare monensin as an ingredient.\u003C\u002Fp>\u003Cp>Therefore, you intentionally added the super-potent, adulterated medicated feed to a non-medicated animal food formulation. The deliberate mixing of adulterated food with good food renders the finished product adulterated, regardless of the final concentration of contaminant in the finished food.\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, your Dry Creek High Cow animal food is adulterated.\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the article being adulterated or misbranded is prohibited.\u003Cem>\u003Cstrong>\u003Csup>15\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Animal Food\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your medicated feed and animal food labeling collected during the inspection and found evidence that some of your products were misbranded under the FD&amp;C Act. Specifically:\u003C\u002Fp>\u003Cp>4. According to your “Reconditioning Proposal,” you used the recalled medicated Bliss Calf Starter feed containing monensin and a non-medicated animal food to produce a medicated feed containing a calculated level of 9.66 g\u002Fton of monensin. The resulting medicated animal feed, Dry Creek High Cow, bore a label that failed to declare the drug, monensin, and its quantity. The failure of your product’s label to declare the name and quantity of each active ingredient causes the product to be misbranded.\u003Cem>\u003Cstrong>\u003Csup>16\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>5. As noted above, your label for the Type C Bliss Calf Starter medicated feed states, “Feed as directed by nutritionist.” This labeling does not conform to the approved representative (“\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) labeling for monensin Type C medicated feed and does not bear adequate directions for use. Your label also does not include indications for use. Failure to bear adequate directions for use causes your Bliss Calf Starter medicated feed product to be misbranded.\u003Cem>\u003Cstrong>\u003Csup>17\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Reportable Food Registry (RFR)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>You failed to report a reportable food to the RFR within 24 hours of determining that an article of food is reportable food (an article of food for which there is reasonable probability that the use of, or exposure to, such article of food will cause serious adverse health consequences or death to humans or animals), as required by section 417(d)(1) of the FD&amp;C Act [21 U.S.C. § 350f(d)(1)].\u003C\u002Fp>\u003Cp>Specifically, on October 20, 2024, you were informed by your customer of multiple calf deaths which occurred after the calves consumed your Bliss Calf Starter cattle medicated feed. You recalled this cattle feed between October 21-24, 2024, and sent samples of the feed to a third-party laboratory for analysis. On October 30, 2024, you received the third-party laboratory results that reported that the feed contained a super-potent concentration (276 g\u002Fton) of monensin. However, you did not file the reportable food report until November 11, 2024.\u003C\u002Fp>\u003Cp>The RFR was established to provide a reliable mechanism to track patterns of adulteration in food (including animal food) to support efforts by FDA to target limited inspection resources to protect public health. It requires a “responsible party” to file reportable food reports. The responsible party is the person who submits the registration under section 415 of the FD&amp;C Act required for a food facility that is required to register, at which the reportable food was manufactured, processed, packed, or held.\u003Cem>\u003Cstrong>\u003Csup>18\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The responsible party is required to file a notification within 24 hours of determining that an article of food is a reportable food. Failure to submit a required reportable food report is a prohibited act under the FD&amp;C Act.\u003Cem>\u003Cstrong>\u003Csup>19\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>For more information about the requirements of 21 CFR Part 507, 225, and 558, see:\u003C\u002Fp>\u003Cp>• Guidance for Industry #235, Current Good Manufacturing Practice Requirements for Food for Animals https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\u003C\u002Fp>\u003Cp>• Guidance for Industry #245, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\u003C\u002Fp>\u003Cp>• Draft Guidance for Industry #246, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\u003C\u002Fp>\u003Cp>• Medicated Feeds: https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fanimal-food-feeds\u002Fmedicated-feeds\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe your products are not in violation of the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>The Food &amp; Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\u003C\u002Fp>\u003Cp>Please direct your electronic correspondence to Compliance Officer Andrew Howard at Andrew.Howard@fda.hhs.gov.\u003C\u002Fp>\u003Cp>If you have questions regarding this letter, please contact Compliance Officer Andrew Howard by telephone at (410) 779-5125, or by email at Andrew.Howard@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Isaac K. Carney\u003Cbr>Director of Food Compliance, Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003Cbr>U.S. Food and Drug Administration\u003Cbr>U.S. Department of Health and Human Services\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003Cbr>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 342(uu)].\u003Cbr>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 512(a)(2)(A)(i) of the FD&amp;C Act [21 U.S.C. § 360b(a)(2)(A)(i)].\u003Cbr>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See Section 501(a)(6) of the FD&amp;C Act [21 U.S.C. § 351(a)(6)].&nbsp;\u003Cbr>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See Section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B) and 21 CFR 225.1(b)(1)].\u003Cbr>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See Section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)].\u003Cbr>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See Section 502(e)(1)(A)(ii) of the FD&amp;C Act [21 U.S.C. § 352(e)(1)(A)(ii)].\u003Cbr>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003Cbr>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> See Section 417(d) of the FD&amp;C Act [21 U.S.C. § 350f(d)].\u003Cbr>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(mm) of the FD&amp;C Act [21 U.S.C. § 331(mm)].&nbsp;\u003Cbr>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR 507.27(b).\u003Cbr>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 558.355 and https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002Fdocument\u002FdownloadBBL\u002F3765.\u003Cbr>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> See Compliance Policy Guide Sec 555.200 Adulterated Food Mixed with Good Food, https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcpg-sec-555200-adulterated-food-mixed-good-food.\u003Cbr>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(2)(C)(ii) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(ii)].\u003Cbr>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003Cbr>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> See section 502(e)(1)(A)(ii) of the FD&amp;C Act [21 U.S.C. § 352(e)(1)(A)(ii)].&nbsp;\u003Cbr>\u003Cem>\u003Cstrong>17\u003C\u002Fstrong>\u003C\u002Fem> See section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)].\u003Cbr>\u003Cem>\u003Cstrong>18\u003C\u002Fstrong>\u003C\u002Fem> See Sections 415 and 417(a)(1) of the FD&amp;C Act [21 U.S.C. §§ 350d and 350f(a)(1)].\u003Cbr>\u003Cem>\u003Cstrong>19\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(mm) of the FD&amp;C Act [21 U.S.C. § 331(mm)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nBradley R. More\n\nRecipient Title\n\nPlant Manager\n\nJ.D. Heiskell Holdings LLC\n\n2407 Warren Ave\n\nTwin Falls, ID 83301-7978\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nCMS # 700893\nJune 12, 2025\nDear Bradley More,\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your unlicensed feed mill that manufactures both medicated and non-medicated animal food, located at 2407 Warren Avenue, Twin Falls, Idaho, from December 2 to 5, 2024. The inspection was initiated in response to a Reportable Food Registry (RFR) report your firm filed on November 11, 2024, after receiving a consumer complaint on October 20, 2024, reporting multiple deaths of calves after consuming your Bliss Calf Starter medicated feed product. Your third-party lab analyzed samples of feed from the customer and reported the presence of excessive monensin in one lot of Bliss Calf Starter. You initiated a voluntary Class I recall of this medicated feed due to excessive monensin on October 21, 2024. We received and evaluated your written response to the Form FDA 483, Inspectional Observations, (FDA 483) dated December 9, 2024.\nDuring the inspection, the FDA investigator found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements found in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which causes your products to be adulterated because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.1 In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR Part 507 is prohibited.2\nIn addition, the FDA investigator found evidence that you manufactured and distributed Bliss Calf Starter medicated feed that contained a super-potent concentration of the new animal drug monensin. This Type C medicated cattle feed containing the Type A medicated article of monensin is unsafe because the new animal drug was not used in conformance with the drug approval because the quantity in the final feed exceeded the approved safe level for use in cattle feed.3 As a result, the Bliss Calf Starter medicated feed containing the new animal drug is adulterated.4\nFurther, the inspection revealed evidence of significant violations of Current Good Manufacturing Practice (CGMP) for Medicated Feeds, 21 CFR Part 225. Failure of your medicated feed mill to comply with these requirements also causes your medicated and non-medicated feeds to be adulterated.5\nAdditionally, your Bliss Calf Starter feed is misbranded because its labeling does not bear adequate directions for use.6 As described further below, you attempted to recondition the Bliss Calf Starter medicated feed containing a super-potent concentration of monensin by mixing the feed into your non-medicated Dry Creek High Cow formulation. Therefore, your Dry Creek High Cow feed is also misbranded because its label does not bear the name and quantity of each active ingredient.7\nThe doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the article being adulterated or misbranded is prohibited.8\nFurthermore, you failed to report a reportable food to the RFR within twenty-four hours of determining that it is a reportable food (i.e., an animal food for which there is a reasonable probability that the use of, or exposure to, such animal food will cause serious adverse health consequences or death to animals).9 Failure to submit a required reportable food report is a prohibited act.10\nYou may find the FD&C Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\nAt the close of the inspection, you were issued an FDA 483. As noted above, we received your written response dated December 9, 2024. We have reviewed your response and address your corrective actions below in relation to each of the noted violations.\nHazard Analysis and Risk-Based Preventive Controls Requirements\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA investigator observed evidence of significant violations of these requirements, which included the following:\n1. You failed to sufficiently assess the probability that a hazard will occur in the absence of preventive controls, as required by 21 CFR 507.33(c)(1).\na. Your hazard analysis identified that excess animal drug due to “weighing error” is a known or reasonably foreseeable hazard, and you determined that a preventive control was not required due to your prerequisite program. Specifically, your hazard analysis indicates that you will control the hazard at the “(b)(4)” step through the use of “(b)(4) Procedure” and (b)(4) verification prerequisite programs.\nHowever, your prerequisite program was not implemented in a way that reduces the probability of occurrence of the hazard, as evidenced by the excessive monensin in batch (b)(4) of your Bliss Calf Starter medicated feed. On October 13, 2024, your employee added 169.6 lbs. of monensin to this batch of Bliss Calf Starter medicated feed, which exceeds the (b)(4) lbs. of monensin that is called for in this formulation of feed and resulted in a calculated super-potent concentration of 476 g\u002Fton in the finished calf feed. After a customer notified you of calf deaths after consuming the Bliss Calf Starter medicated feed, your facility collected and submitted samples of the feed to a third-party laboratory, which found that it contained 276 g\u002Fton of monensin. Therefore, you did not reduce the probability that the excess animal drug hazard would occur in the absence of a preventive control.\nEvaluation of your response:\nDuring the inspection and in your written response dated December 9, 2024, you stated that you made corrections including verifying the drug log and monitoring the accuracy of (b)(4) adds (b)(4) and amending your “(b)(4) and (b)(4) SOP 208” procedure for drug quantities to be entered into your electronic usage report. However, we are unable to fully evaluate your corrective actions since you did not provide supporting documentation to demonstrate that these corrections have been implemented or that employees have been trained regarding the updated procedure. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nb. Your hazard analysis identified at the “Rework & Returned Material” manufacturing step that you are controlling the “(b)(4)” hazard using your “Rework Plan” as a prerequisite program. However, you stated during the inspection that you did not have a rework written procedure. If you rely on a prerequisite program in your evaluation of the probability of occurrence of a hazard, adequate information about the prerequisite program must be included in your hazard analysis as part of your evaluation.\nFurthermore, despite your claimed prerequisite program, you mixed the recalled Bliss Calf Starter medicated feed containing monensin with a non-medicated customer-formula animal food to produce a reworked product labeled Dry Creek High Cow which you estimated contained 9.66 g\u002Fton of monensin. The Dry Creek High Cow food was not labeled to contain monensin. Therefore, your prerequisite program does not reduce the probability of the hazard of medication in a non-medicated animal food in the absence of a preventive control.\nEvaluation of your response:\nYour written response to the FDA 483 stated that you intend to establish a written standard operating procedure for reconditioning feed within the next 90 days, which will include a written rework plan and records that accurately document how feed is reconditioned. To date, we have not received a copy of the procedure or records to demonstrate your corrections have been implemented. Therefore, we are unable to fully evaluate your corrective actions. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nc. Your reliance on prerequisite programs failed to reduce the probability that mycotoxins would occur in your animal food ingredients in the absence of a preventive control. Your hazard analysis identified mycotoxins, under “Natural toxins,” as a potential hazard for animal food ingredients including corn, soybeans, and wheat, and indicates that you will control the hazard with your preferred supplier program and “Quality Sample Schedule” prerequisite programs. However, our investigator found no evidence that you are following your prerequisite programs. For example, your sampling procedure states that each commodity will be tested for mycotoxins (b)(4). You were unable to provide any records to demonstrate that any of the ingredients susceptible to mycotoxins were sampled and analyzed for the presence of mycotoxins since March 2023.\nEvaluation of your response:\nYour response dated December 9, 2024, stated that your “Quality Sampling Schedule” procedure was not reflective of the actual sampling conducted at your establishment and that you will begin testing each commodity for mycotoxins (b)(4). However, you did not provide any documentation to demonstrate the implementation of your corrective actions. Furthermore, you did not provide any justification that (b)(4) analysis per commodity will be sufficient to control mycotoxins in the grain ingredients you use to manufacture animal food. Therefore, we are unable to fully evaluate the corrections you have made. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\nMedicated Feed Current Good Manufacturing Practice Requirements\nYour facility is required to follow the medicated feed CGMP regulations for non-licensed, medicated animal feed manufacturers found in 21 CFR 225.120-202. During the inspection, the FDA investigator observed evidence of violations of these requirements, which included:\n2. You did not establish and maintain adequate procedures for the identification, storage, and inventory control (receipt and use) of all Type A medicated articles and Type B medicated feeds intended for use in the manufacture of medicated feed to aid in assuring the identity, strength, quality, and purity of these drug sources. All Type A medicated articles and Type B medicated feeds must be used in accordance with their labeled mixing directions, as required by 21 CFR 225.142. Specifically:\na. While your formula for Bliss Calf Starter medicated feed called for (b)(4) lbs. of monensin (consistent with the labeled mixing directions), your records show that on October 13, 2024, your employee added 169.6 lbs. of monensin to batch (b)(4) of your Bliss Calf Starter medicated feed.\nYour “(b)(4) and (b)(4) SOP 208” was not adequate because it did not prevent the weighing error that resulted in a super-potent medicated feed that contained excessive monensin. Furthermore, you had no documentation that your drug log or batch records were verified by anyone for accuracy (theoretical usage based on formula versus actual medicated article pulled from inventory) prior to the distribution of your Bliss Calf Starter medicated feed, batch (b)(4).\nb. During the inspection, you provided a reconditioning proposal, dated November 15, 2024, which documented your plan to manufacture Dry Creek High Cow animal food that is intended to be non-medicated. The proposal shows that the Dry Creek High Cow food would be combined with the recalled super-potent Bliss Calf Starter medicated feed, which you manufactured from the Type A medicated article monensin. This proposal does not document procedures for reworking medicated feed in a way that aids in assuring that Type A drug components maintain the identity, strength, quality, and purity throughout manufacturing at your facility and so that Type A medicated articles and Type B medicated feeds are used in accordance with their labeled mixing directions. Additionally, while you explained to the FDA investigator that the Dry Creek High Cow feed was manufactured in a (b)(4), this is not reflected in the reconditioning proposal.\nEvaluation of your response:\nIn your written response dated December 9, 2024, you stated that your corrections included verifying the accuracy of the drug log (b)(4) and amending your “(b)(4) and (b)(4) SOP 208” procedure for drug quantities to be entered into your electronic usage report. You also stated that you intend to create a rework procedure and implementation records. However, your response did not include supporting documentation to demonstrate that these corrections have been implemented or that employees have been trained regarding the updated procedure. Therefore, we are unable to fully evaluate your corrections. We encourage you to provide us with documentation of implementation of your corrections in follow-up correspondence.\n3. You failed to ensure that all deliveries of medicated feeds, whether bagged or in bulk, are adequately labeled to assure that the feed can properly be used, as required by 21 CFR 225.180.11\nSpecifically, your Type C Bliss Calf Starter medicated feed label did not include adequate feeding directions set forth in the new animal drug approval for monensin-medicated cattle feed for the labeled monensin concentration of 60.9 g\u002Fton, nor indications for use. Your label states, “Feed as directed by nutritionist.” We note that feeding directions and indications for use are sections included in the representative (“(b)(4)”) labeling for monensin-medicated cattle feed.12\nEvaluation of your response:\nIn your written response dated December 9, 2024, you stated you intend to verify and update the necessary feed labels. However, you have not provided updated feed labels to demonstrate your corrections have been implemented. We are, therefore, unable to fully evaluate the corrections you have made.\nAttempted Reconditioning of Adulterated Animal Food\nIn your reconditioning proposal, you documented that you attempted to recondition the Bliss Calf Starter feed, batch (b)(4), which contained a super-potent concentration of monensin (the “super-potent” feed), by mixing the super-potent feed with your standard-formulated Bliss Calf Starter feed, containing 60 g\u002Fton monensin, to create an unspecified lot of Blended Bliss Calf Starter feed containing a calculated 154.6316 g\u002Fton of monensin. You then mixed the Blended Bliss Calf Starter feed with non-medicated Dry Creek High Cow food to create at least (b)(4) lots containing a calculated 9.6644 g\u002Fton of monensin. You labeled the finished product as Dry Creek High Cow, and its labeling did not declare monensin as an ingredient.\nTherefore, you intentionally added the super-potent, adulterated medicated feed to a non-medicated animal food formulation. The deliberate mixing of adulterated food with good food renders the finished product adulterated, regardless of the final concentration of contaminant in the finished food.13 Therefore, your Dry Creek High Cow animal food is adulterated.14 The doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the article being adulterated or misbranded is prohibited.15\nMisbranded Animal Food\nFDA reviewed your medicated feed and animal food labeling collected during the inspection and found evidence that some of your products were misbranded under the FD&C Act. Specifically:\n4. According to your “Reconditioning Proposal,” you used the recalled medicated Bliss Calf Starter feed containing monensin and a non-medicated animal food to produce a medicated feed containing a calculated level of 9.66 g\u002Fton of monensin. The resulting medicated animal feed, Dry Creek High Cow, bore a label that failed to declare the drug, monensin, and its quantity. The failure of your product’s label to declare the name and quantity of each active ingredient causes the product to be misbranded.16\n5. As noted above, your label for the Type C Bliss Calf Starter medicated feed states, “Feed as directed by nutritionist.” This labeling does not conform to the approved representative (“(b)(4)”) labeling for monensin Type C medicated feed and does not bear adequate directions for use. Your label also does not include indications for use. Failure to bear adequate directions for use causes your Bliss Calf Starter medicated feed product to be misbranded.17\nReportable Food Registry (RFR)\nYou failed to report a reportable food to the RFR within 24 hours of determining that an article of food is reportable food (an article of food for which there is reasonable probability that the use of, or exposure to, such article of food will cause serious adverse health consequences or death to humans or animals), as required by section 417(d)(1) of the FD&C Act [21 U.S.C. § 350f(d)(1)].\nSpecifically, on October 20, 2024, you were informed by your customer of multiple calf deaths which occurred after the calves consumed your Bliss Calf Starter cattle medicated feed. You recalled this cattle feed between October 21-24, 2024, and sent samples of the feed to a third-party laboratory for analysis. On October 30, 2024, you received the third-party laboratory results that reported that the feed contained a super-potent concentration (276 g\u002Fton) of monensin. However, you did not file the reportable food report until November 11, 2024.\nThe RFR was established to provide a reliable mechanism to track patterns of adulteration in food (including animal food) to support efforts by FDA to target limited inspection resources to protect public health. It requires a “responsible party” to file reportable food reports. The responsible party is the person who submits the registration under section 415 of the FD&C Act required for a food facility that is required to register, at which the reportable food was manufactured, processed, packed, or held.18 The responsible party is required to file a notification within 24 hours of determining that an article of food is a reportable food. Failure to submit a required reportable food report is a prohibited act under the FD&C Act.19\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure, and injunction.\nFor more information about the requirements of 21 CFR Part 507, 225, and 558, see:\n• Guidance for Industry #235, Current Good Manufacturing Practice Requirements for Food for Animals https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\n• Guidance for Industry #245, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\n• Draft Guidance for Industry #246, Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\n• Medicated Feeds: https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fanimal-food-feeds\u002Fmedicated-feeds\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe your products are not in violation of the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\nThe Food & Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\nPlease direct your electronic correspondence to Compliance Officer Andrew Howard at Andrew.Howard@fda.hhs.gov.\nIf you have questions regarding this letter, please contact Compliance Officer Andrew Howard by telephone at (410) 779-5125, or by email at Andrew.Howard@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nIsaac K. Carney\nDirector of Food Compliance, Office of Surveillance and Compliance\nCenter for Veterinary Medicine\nU.S. Food and Drug Administration\nU.S. Department of Health and Human Services\n_____________________________\n1 See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n2 See Section 301(uu) of the FD&C Act [21 U.S.C. § 342(uu)].\n3 See Section 512(a)(2)(A)(i) of the FD&C Act [21 U.S.C. § 360b(a)(2)(A)(i)].\n4 See Section 501(a)(6) of the FD&C Act [21 U.S.C. § 351(a)(6)].\n5 See Section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B) and 21 CFR 225.1(b)(1)].\n6 See Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)].\n7 See Section 502(e)(1)(A)(ii) of the FD&C Act [21 U.S.C. § 352(e)(1)(A)(ii)].\n8 See Section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].\n9 See Section 417(d) of the FD&C Act [21 U.S.C. § 350f(d)].\n10 See Section 301(mm) of the FD&C Act [21 U.S.C. § 331(mm)].\n11 See also 21 CFR 507.27(b).\n12 See 21 CFR 558.355 and https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002Fdocument\u002FdownloadBBL\u002F3765.\n13 See Compliance Policy Guide Sec 555.200 Adulterated Food Mixed with Good Food, https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcpg-sec-555200-adulterated-food-mixed-good-food.\n14 See Section 402(a)(2)(C)(ii) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(ii)].\n15 See Section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].\n16 See section 502(e)(1)(A)(ii) of the FD&C Act [21 U.S.C. § 352(e)(1)(A)(ii)].\n17 See section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)].\n18 See Sections 415 and 417(a)(1) of the FD&C Act [21 U.S.C. §§ 350d and 350f(a)(1)].\n19 See Section 301(mm) of the FD&C Act [21 U.S.C. § 331(mm)].","J.D. Heiskell Holdings LLC","jd-heiskell-holdings-llc-700893-06122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjd-heiskell-holdings-llc-700893-06122025","2026-10-26T08:09:03.405921+00:00","Closed Out","2025-07-08","700893","Animal & Veterinary","2026-03-27","Bradley R. More","2026-08-19T16:37:22.328+00:00","VIA EMAIL WITH READ RECEIPT","2025-06-12",{"id":125,"raw":126,"subject":131,"body_html":132,"body_text":133,"firm_name":134,"letter_id":135,"created_at":136,"fei_number":20,"letter_url":137,"updated_at":138,"action_type":23,"case_status":24,"posted_date":139,"marcs_cms_no":140,"product_type":27,"closeout_date":20,"issuing_office":130,"recipient_name":141,"body_fetched_at":142,"delivery_method":143,"recipient_title":20,"reference_number":144,"action_taken_date":145,"medical_device_id":20,"response_letter_date":20},117,[127,128,129,130,131,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frevlon-group-holdings-llc-722596-06022026\">Revlon Group Holdings, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-89\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David Hamilton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Operations  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Revlon Group Holdings, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1501 Williamsboro St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Oxford\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27565\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-89\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Hamilton:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 8, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Revlon – Oxford Facility, FEI 1021184, at 1501 Williamsboro St., Oxford, as well as subsequent correspondence.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violation were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product labeled to contain the active drug ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You currently manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug product labeled to contain the active drug ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These drug products listed above are labeled to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\u003C\u002Fp>\u003Cp>You have not demonstrated that you appropriately tested incoming talc drug components used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you originally indicated that you did perform testing for asbestos in talc before release for use in drug product manufacturing. In subsequent correspondence, the data you provided only clarified that your talc components were tested for asbestos by the supplier and not by you. Evidence was not provided that your firm conducts asbestos testing at your facility. You failed to provide records indicating that you established the reliability of your supplier’s analyses through appropriate validation of the supplier’s test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals.\u003C\u002Fp>\u003Cp>Additionally, you provided records to demonstrate you had conducted identity testing pursuant to the applicable United States Pharmacopeia (USP) test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), but the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification B and C). Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Identity, assay and impurity test results from testing retains for all lots of talc (drug component) used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A gap analysis for specifications for drug components (active and inactive) between your current specifications and test procedures against the USP, where applicable. Based on your gap analysis, provide a comprehensive plan for conformance of your drug component specifications and testing to USP standards, where applicable.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current USP talc monograph could be used to meet this requirement for talc; however, your specifications for talc components did not include testing for assay, and multiple impurities (e.g., limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Beyond the deficiencies in testing detailed above, your talc microbiological specifications for “yeast and mold” of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg exceeds USP specification for total combined molds and yeasts of Not More Than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg for talc used in \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Your COA reports microbiological test results as \"CONFORM\" without including a quantitative value, which would not be sufficient for the QU to make an informed release decision or determine if the result meets the USP requirement. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003Cli>A complete and final review of representative batches within expiry and their related information before the QU disposition decision\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Practice of Releasing Drug Products Close to Expiration\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of documents you provided, you released multiple lots of OTC drug products within a few months of expiry, including one released with only 1 month before the drug product expiry. Of note, FDA documented instances of drug products that you discontinued, and past your expiration date, for sale online well after they expired, which could be attributed to your practice of distributing drugs close to expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Reformulation to No Longer Use Talc in High-Risk Dosage Forms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response to our additional request for records you indicated that you would be reformulating your drug products containing talc. In response to this letter provide an update on your reformulation efforts to move to an alternative not associated with risks of talc.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Specifications Regarding Talc\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Talc is a USP article, whose specification can be found in the current USP talc monograph. As\u003Cbr>mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that\u003Cbr>drugs including components, such as talc, that are recognized in the USP are generally required\u003Cbr>to meet the current applicable USP monograph under section 501(b) of the FD&amp;C Act. FDA\u003Cbr>reviewed your specifications for talc components and they are incomplete when compared to the\u003Cbr>current USP specification. We note that the USP has recently revised its monograph for talc\u003Cbr>which includes updated technical requirements for asbestos testing in talc and is currently\u003Cbr>scheduled to be official in June 2026.&nbsp;\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1021184 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cstrong>2\u003C\u002Fstrong> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-89\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. David Hamilton\n\nRecipient Title\n\nVice President of Operations\n\nRevlon Group Holdings, LLC\n\n1501 Williamsboro St.\n\nOxford, NC 27565\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-89\nJune 2, 2026\nDear Mr. Hamilton:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 8, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Revlon – Oxford Facility, FEI 1021184, at 1501 Williamsboro St., Oxford, as well as subsequent correspondence.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violation were observed including, but not limited to, the following:\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\nYour firm manufactured (b)(4), an OTC (b)(4) drug product labeled to contain the active drug ingredient (b)(4). You currently manufacture (b)(4) OTC drug product labeled to contain the active drug ingredient (b)(4). These drug products listed above are labeled to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Your (b)(4) drug product, (b)(4), is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\nYou have not demonstrated that you appropriately tested incoming talc drug components used in the manufacture of your (b)(4) drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you originally indicated that you did perform testing for asbestos in talc before release for use in drug product manufacturing. In subsequent correspondence, the data you provided only clarified that your talc components were tested for asbestos by the supplier and not by you. Evidence was not provided that your firm conducts asbestos testing at your facility. You failed to provide records indicating that you established the reliability of your supplier’s analyses through appropriate validation of the supplier’s test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals.\nAdditionally, you provided records to demonstrate you had conducted identity testing pursuant to the applicable United States Pharmacopeia (USP) test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), but the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification B and C). Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nIdentity, assay and impurity test results from testing retains for all lots of talc (drug component) used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\nA description of how you will test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\nThe chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\nA gap analysis for specifications for drug components (active and inactive) between your current specifications and test procedures against the USP, where applicable. Based on your gap analysis, provide a comprehensive plan for conformance of your drug component specifications and testing to USP standards, where applicable.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current USP talc monograph could be used to meet this requirement for talc; however, your specifications for talc components did not include testing for assay, and multiple impurities (e.g., limits of (b)(4)). Beyond the deficiencies in testing detailed above, your talc microbiological specifications for “yeast and mold” of (b)(4) cfu\u002Fg exceeds USP specification for total combined molds and yeasts of Not More Than (NMT) (b)(4) cfu\u002Fg for talc used in (b)(4) drug products. Your COA reports microbiological test results as \"CONFORM\" without including a quantitative value, which would not be sufficient for the QU to make an informed release decision or determine if the result meets the USP requirement. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nA complete and final review of representative batches within expiry and their related information before the QU disposition decision\nPractice of Releasing Drug Products Close to Expiration\nBased on a review of documents you provided, you released multiple lots of OTC drug products within a few months of expiry, including one released with only 1 month before the drug product expiry. Of note, FDA documented instances of drug products that you discontinued, and past your expiration date, for sale online well after they expired, which could be attributed to your practice of distributing drugs close to expiry.\nReformulation to No Longer Use Talc in High-Risk Dosage Forms\nIn your response to our additional request for records you indicated that you would be reformulating your drug products containing talc. In response to this letter provide an update on your reformulation efforts to move to an alternative not associated with risks of talc.\nQuality Specifications Regarding Talc\nTalc is a USP article, whose specification can be found in the current USP talc monograph. As\nmentioned above, the specific test for asbestos is included in the talc monograph. Be advised that\ndrugs including components, such as talc, that are recognized in the USP are generally required\nto meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA\nreviewed your specifications for talc components and they are incomplete when compared to the\ncurrent USP specification. We note that the USP has recently revised its monograph for talc\nwhich includes updated technical requirements for asbestos testing in talc and is currently\nscheduled to be official in June 2026.\n\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1021184 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F","Revlon Group Holdings, LLC","revlon-group-holdings-llc-722596-06022026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frevlon-group-holdings-llc-722596-06022026","2026-10-26T08:09:49.211168+00:00","2026-06-09","722596","Mr. David Hamilton","2026-08-19T04:38:12.564+00:00","VIA UPS","320-26-89","2026-06-02",{"id":147,"raw":148,"subject":153,"body_html":154,"body_text":155,"firm_name":156,"letter_id":157,"created_at":67,"fei_number":20,"letter_url":158,"updated_at":159,"action_type":23,"case_status":24,"posted_date":160,"marcs_cms_no":161,"product_type":162,"closeout_date":20,"issuing_office":163,"recipient_name":164,"body_fetched_at":165,"delivery_method":166,"recipient_title":20,"reference_number":20,"action_taken_date":167,"medical_device_id":20,"response_letter_date":20},1434,[149,150,151,152,153,13,13,13],"\u003Ctime datetime=\"2024-06-04T20:30:00Z\">06\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-07T05:00:00Z\">02\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrexo-robotics-holdings-inc-673150-02072024\">Trexo Robotics Holdings Inc.\u003C\u002Fa>","&quot;OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality&quot;","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device, Misbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Manmeet Maggu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Trexo Robotics Holdings Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6705 Millcreek Drive, Unit 3\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mississauga\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L5N 5M4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@trexorobotics.com\"> (b)(6)@trexorobotics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>10903 New Hampshire Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>White Oak Building 66\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Silver Spring\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20993\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER CMS #673150\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 07, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Manmeet Maggu:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Mississauga, Ontario, Canada on June 3 through June 5, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Trexo Home and Trexo Plus medical devices, hereafter referred to as the Trexo devices, and offers the product for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Based on the evidence collected during the June 2023 inspection and other information, including statements on your firm’s website, www.trexorobotics.com, last reviewed on October 05, 2023, FDA has determined that the Trexo devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Trexo devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction this device into interstate commerce for commercial distribution without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81.\u003C\u002Fp>\n\n\u003Cp>You have listed the Trexo devices under classification regulation 21 CFR 890.1925. Devices classified under 21 CFR 890.1925, Isokinetic Testing and Evaluation System, are exempt from premarket notification unless they exceed the limitations of exemption at 21 CFR 890.9(a). Based on evidence collected during FDA’s inspection and a review of your firm’s website, FDA has determined that the Trexo devices are intended for uses that are different from those of legally marketed devices in the generic type of device under 21 CFR 890.1925, Isokinetic Testing and Evaluation System. Generic devices of this type are rehabilitative exercise devices intended for medical purposes, such as to measure, evaluate, and increase the strength of muscles&nbsp;and the range of motion of joints. However, your firm is marketing the Trexo devices for a different intended use; specifically, as a robotic powered gait training device to assist children with different levels of disability with ambulatory functions such as walking and standing. For example, statements made by your firm in labeling include the following:\u003C\u002Fp>\n\n\u003Cp>• “Introducing Trexo Robotic legs to help children with mobility challenges get upright and walk independently.”\u003Cbr>\n• “Depending on your child’s needs, you may adjust the amount of weight bearing, the gait pattern, speed of the device, and level of assist. The active assist feature may be used by children who have some ability to initiate steps or walk.”\u003C\u002Fp>\n\n\u003Cp>Because the Trexo is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.1925, it exceeds the limitations described in 21 CFR 890.9(a) thus requires approval prior to marketing.\u003C\u002Fp>\n\n\u003Cp>In addition, your device appears to operate using a different fundamental scientific technology than legally marketed devices in the generic type of device under 21 CFR 890.1925. For example, based on information in the product manual, the Trexo device use actuators such as a “powered hip joint” (part #1) and a “powered knee joint” (part #5) to generate forces or torques to the swing leg that assist human movement. In contrast, devices classified under 21 CFR 890.1925 are typically stationary machines that consist of a chair or a bench with a resistance mechanism that allows for controlled resistance for measuring muscular performance such as strength, power, and resistance. To the extent the Trexo devices operate using different fundamental scientific technology than legally marketed devices in the generic type of device under 890.1925, they also exceed the limitations of exemption from section 510(k) of the Act as described in 21 CFR 890.9(b).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Manmeet Maggu dated June 30, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s procedures, QMS-S09-730-2, Design and Development Control, Rev 2 (Dated June 7, 2023) and QMS-S09-730-2, Design and Development Control, Rev 1 (Dated May 13, 2023), do not ensure that the design control process has been followed for the Trexo Home and Trexo Plus devices or that design validation was performed under defined operating conditions on the initial production units or the results from design validation were documented in the Device History File (DHF) of the devices.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-39 is related to this observation. The proposed corrective actions include: 1) your firm will be continuing with design change activities according to QMS-SOP-730-1, Design and Development Control, and 2) QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, will be revised to implement design change activities with a proposed completion target date of November 30, 2023. The review of the cited procedure, QMS-SOP-730-1, Design and Development Control, does not address all of the requirements for 21 CFR 820.30. For example, this procedure does not clearly explain how your firm used change control during its design process or how approved design inputs are implemented as part of the change control process.\u003C\u002Fp>\n\n\u003Cp>Additionally, the review of the QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, revealed that this procedure does not address all of the requirements for 21 CFR 820.30(g). For example, this procedure did not summarize how the clinical evaluations of the device ensure the device meets user needs and the intended uses, and this procedure did not clearly define how risk management issues were addressed throughout the design control process for these devices. In addition, it is unclear what design change activities are being conducted and how these design change activities will result in the revision of the QMS-PLN-003.\u003C\u002Fp>\n\n\u003Cp>Your firm should provide evidence that the procedure has been updated to include all of the requirements of 21 CFR 820.30, and evidence of implementation of the validation activities that were conducted as part of the design control process for the Trexo devices.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example: The procedure, QMS-SOP-756-1, Process Validation, Rev 1.0 (dated June 6, 2023) does not ensure that a process that cannot be fully verified has been adequately validated. For example, the PCBA and motor tests for the Trexo Home and Trexo Plus have not been validated.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-53 is related to this observation. The proposed corrective actions include: 1) drafting QMS-DOC-756.001, Required Process Validations, to list all of the processes that require validation and 2) to implement the Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) activities that were specified in QMS-DOC-756.001. Your firm did not indicate if the procedure, QMS-SOP-756-1, Process Validation, would be updated to meet the requirements of 21 CFR 820.75(a). In addition, a copy of the QMS-DOC-756.001 document was not provided for review. Without this document, it is unknown what IQ, OQ and PQ activities are being performed on the Trexo devices. In addition, your firm did not specifically address the criteria that will be utilized in order to conduct the PCBA and motor validation tests\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1).\u003C\u002Fp>\n\n\u003Cp>For example: The procedure, QMS-S09-851-0, Corrective and Preventative Actions (CAPA), Rev. 2 (dated May 1, 2023; and the same procedure, Rev 1, dated April 14, 2023) does not ensure that all data sources are reviewed as possible CAPAs. For example, non-conformance reports (NCRs) are not included as a Quality Objective.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-59 has been initiated in response to this observation. The proposed corrective actions are: 1) to update QMS-DOC-001, Quality Policy &amp; Quality Objectives, to include measurable Key Performance Indicator (KPI) reporting metrics required for NCRs and CAPAs; 2) to revise CEMS-SOP-851-2, Corrective and Preventative Actions, to include all data sources. Your firm did not provide copies of the updated procedures, QMS-DOC-001, Quality Policy &amp; Quality Objectives and QMS-S09-851-0, Corrective and Preventative Actions for review. Your firm’s response does not mention if the updated procedures will be utilized to conduct a retrospective review of past NCRs and CAPAs.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. Such procedures shall ensure that: 1) All complaints are processed in a uniform and timely manner; 2) Oral complaints are documented upon receipt; and 3) Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a).\u003C\u002Fp>\n\n\u003Cp>For example: The procedures, QMS-SOP-821-2, Feedback and Complaint Handling, Rev 2 (dated May 17, 2023 (and the previous version, Rev 1 dated April 21, 2023)) and QMS-WRK-821-1, Feedback and Complaint Work Instructions, Rev 1 (dated June 2, 2023) do&nbsp;not ensure that complaints received by your firm are adequately handled. Specifically:\u003C\u002Fp>\n\n\u003Cp>A. Your procedures do not ensure that all complaints are handled as complaints instead of feedback. Each of the four feedback records should have been designated as complaints but were instead handled as feedback. Feedback records do not require evaluation for MDRs.\u003C\u002Fp>\n\n\u003Cp>B. Your procedures do not ensure complaints that do not require investigations are documented. Five out of seven complaints reviewed did not require investigations due to the investigations being previously investigated. This information was not documented in the five complaints.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time.\u003C\u002Fp>\n\n\u003Cp>Your firm indicated that CAR-46 is related to this observation. The proposed corrective actions are: 1) to retrain the Customer Service Engineer (CSE) on the Feedback and Complaint Handling procedure, QMS-SOP-821-2; 2) to review past tickets to ensure that the tickets were handled correctly as complaints, to evaluate these tickets for compliance with the MDR procedure, and to investigate these tickets (if required); 3) to update the Feedback and Complaint Report, QMS-FRM-821, to reference an ISSUE ID (ISSUE ID group the complaints based on the causes of the complaints); and 4) to update the Feedback and Complaint Work Instruction, QMS-WRK-821, to describe the process of grouping a new complaint to an existing ISSUE ID in order to determine if an investigation is necessary. Without all of the aforementioned supporting evidence, the evidence needed to evaluate the adequacy of this response is incomplete.\u003C\u002Fp>\n\n\u003Cp>Our office requests that your firm, Trexo Robotics Holdings Inc., cease any activities that result in the misbranding or adulteration of the Trexo devices, such as the commercial distribution of the devices for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this&nbsp;Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to: CDRHWarningLetterResponses@fda.hhs.gov or by mail to:&nbsp;\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the identification number CMS #673150 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Heather Dean, Ph.D., Assistant Director, Physical Medicine-Acute Injury Devices Team at (240) 402-9874.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCAPT Nina Mezu-Nwaba, PharmD., MPH., MSc.\u003Cbr>\nDeputy Director\u003Cbr>\nOHT5: Office of Neurological\u003Cbr>\nand Physical Medicine Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nManmeet Maggu\n\nTrexo Robotics Holdings Inc.\n\n6705 Millcreek Drive, Unit 3\n\nMississauga ON L5N 5M4\n\nCanada\n\n(b)(6)@trexorobotics.com\n\nIssuing Office:\n\n\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"\n\n10903 New Hampshire Ave.\n\nWhite Oak Building 66\n\nSilver Spring, MD 20993\n\nUnited States\n\nWARNING LETTER CMS #673150\n\nFebruary 07, 2024\n\nDear Manmeet Maggu:\n\nDuring an inspection of your firm located in Mississauga, Ontario, Canada on June 3 through June 5, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Trexo Home and Trexo Plus medical devices, hereafter referred to as the Trexo devices, and offers the product for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nBased on the evidence collected during the June 2023 inspection and other information, including statements on your firm’s website, www.trexorobotics.com, last reviewed on October 05, 2023, FDA has determined that the Trexo devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Trexo devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction this device into interstate commerce for commercial distribution without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81.\n\nYou have listed the Trexo devices under classification regulation 21 CFR 890.1925. Devices classified under 21 CFR 890.1925, Isokinetic Testing and Evaluation System, are exempt from premarket notification unless they exceed the limitations of exemption at 21 CFR 890.9(a). Based on evidence collected during FDA’s inspection and a review of your firm’s website, FDA has determined that the Trexo devices are intended for uses that are different from those of legally marketed devices in the generic type of device under 21 CFR 890.1925, Isokinetic Testing and Evaluation System. Generic devices of this type are rehabilitative exercise devices intended for medical purposes, such as to measure, evaluate, and increase the strength of muscles and the range of motion of joints. However, your firm is marketing the Trexo devices for a different intended use; specifically, as a robotic powered gait training device to assist children with different levels of disability with ambulatory functions such as walking and standing. For example, statements made by your firm in labeling include the following:\n\n• “Introducing Trexo Robotic legs to help children with mobility challenges get upright and walk independently.”\n\n• “Depending on your child’s needs, you may adjust the amount of weight bearing, the gait pattern, speed of the device, and level of assist. The active assist feature may be used by children who have some ability to initiate steps or walk.”\n\nBecause the Trexo is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.1925, it exceeds the limitations described in 21 CFR 890.9(a) thus requires approval prior to marketing.\n\nIn addition, your device appears to operate using a different fundamental scientific technology than legally marketed devices in the generic type of device under 21 CFR 890.1925. For example, based on information in the product manual, the Trexo device use actuators such as a “powered hip joint” (part #1) and a “powered knee joint” (part #5) to generate forces or torques to the swing leg that assist human movement. In contrast, devices classified under 21 CFR 890.1925 are typically stationary machines that consist of a chair or a bench with a resistance mechanism that allows for controlled resistance for measuring muscular performance such as strength, power, and resistance. To the extent the Trexo devices operate using different fundamental scientific technology than legally marketed devices in the generic type of device under 890.1925, they also exceed the limitations of exemption from section 510(k) of the Act as described in 21 CFR 890.9(b).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Manmeet Maggu dated June 30, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nFor example: Your firm’s procedures, QMS-S09-730-2, Design and Development Control, Rev 2 (Dated June 7, 2023) and QMS-S09-730-2, Design and Development Control, Rev 1 (Dated May 13, 2023), do not ensure that the design control process has been followed for the Trexo Home and Trexo Plus devices or that design validation was performed under defined operating conditions on the initial production units or the results from design validation were documented in the Device History File (DHF) of the devices.\n\nWe reviewed your firm’s response and concluded that it is not adequate.\n\nYour firm indicated that CAR-39 is related to this observation. The proposed corrective actions include: 1) your firm will be continuing with design change activities according to QMS-SOP-730-1, Design and Development Control, and 2) QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, will be revised to implement design change activities with a proposed completion target date of November 30, 2023. The review of the cited procedure, QMS-SOP-730-1, Design and Development Control, does not address all of the requirements for 21 CFR 820.30. For example, this procedure does not clearly explain how your firm used change control during its design process or how approved design inputs are implemented as part of the change control process.\n\nAdditionally, the review of the QMS-PLN-003, Trexo Home\u002FPlus Verification and Validation Plan, revealed that this procedure does not address all of the requirements for 21 CFR 820.30(g). For example, this procedure did not summarize how the clinical evaluations of the device ensure the device meets user needs and the intended uses, and this procedure did not clearly define how risk management issues were addressed throughout the design control process for these devices. In addition, it is unclear what design change activities are being conducted and how these design change activities will result in the revision of the QMS-PLN-003.\n\nYour firm should provide evidence that the procedure has been updated to include all of the requirements of 21 CFR 820.30, and evidence of implementation of the validation activities that were conducted as part of the design control process for the Trexo devices.\n\n2. Failure to adequately establish and maintain procedures where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\n\nFor example: The procedure, QMS-SOP-756-1, Process Validation, Rev 1.0 (dated June 6, 2023) does not ensure that a process that cannot be fully verified has been adequately validated. For example, the PCBA and motor tests for the Trexo Home and Trexo Plus have not been validated.\n\nWe reviewed your firm’s response and concluded that it is not adequate.\n\nYour firm indicated that CAR-53 is related to this observation. The proposed corrective actions include: 1) drafting QMS-DOC-756.001, Required Process Validations, to list all of the processes that require validation and 2) to implement the Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) activities that were specified in QMS-DOC-756.001. Your firm did not indicate if the procedure, QMS-SOP-756-1, Process Validation, would be updated to meet the requirements of 21 CFR 820.75(a). In addition, a copy of the QMS-DOC-756.001 document was not provided for review. Without this document, it is unknown what IQ, OQ and PQ activities are being performed on the Trexo devices. In addition, your firm did not specifically address the criteria that will be utilized in order to conduct the PCBA and motor validation tests\n\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1).\n\nFor example: The procedure, QMS-S09-851-0, Corrective and Preventative Actions (CAPA), Rev. 2 (dated May 1, 2023; and the same procedure, Rev 1, dated April 14, 2023) does not ensure that all data sources are reviewed as possible CAPAs. For example, non-conformance reports (NCRs) are not included as a Quality Objective.\n\nWe reviewed your firm’s response and concluded that it is not adequate.\n\nYour firm indicated that CAR-59 has been initiated in response to this observation. The proposed corrective actions are: 1) to update QMS-DOC-001, Quality Policy & Quality Objectives, to include measurable Key Performance Indicator (KPI) reporting metrics required for NCRs and CAPAs; 2) to revise CEMS-SOP-851-2, Corrective and Preventative Actions, to include all data sources. Your firm did not provide copies of the updated procedures, QMS-DOC-001, Quality Policy & Quality Objectives and QMS-S09-851-0, Corrective and Preventative Actions for review. Your firm’s response does not mention if the updated procedures will be utilized to conduct a retrospective review of past NCRs and CAPAs.\n\n4. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. Such procedures shall ensure that: 1) All complaints are processed in a uniform and timely manner; 2) Oral complaints are documented upon receipt; and 3) Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a).\n\nFor example: The procedures, QMS-SOP-821-2, Feedback and Complaint Handling, Rev 2 (dated May 17, 2023 (and the previous version, Rev 1 dated April 21, 2023)) and QMS-WRK-821-1, Feedback and Complaint Work Instructions, Rev 1 (dated June 2, 2023) do not ensure that complaints received by your firm are adequately handled. Specifically:\n\nA. Your procedures do not ensure that all complaints are handled as complaints instead of feedback. Each of the four feedback records should have been designated as complaints but were instead handled as feedback. Feedback records do not require evaluation for MDRs.\n\nB. Your procedures do not ensure complaints that do not require investigations are documented. Five out of seven complaints reviewed did not require investigations due to the investigations being previously investigated. This information was not documented in the five complaints.\n\nThe adequacy of your firm’s response cannot be determined at this time.\n\nYour firm indicated that CAR-46 is related to this observation. The proposed corrective actions are: 1) to retrain the Customer Service Engineer (CSE) on the Feedback and Complaint Handling procedure, QMS-SOP-821-2; 2) to review past tickets to ensure that the tickets were handled correctly as complaints, to evaluate these tickets for compliance with the MDR procedure, and to investigate these tickets (if required); 3) to update the Feedback and Complaint Report, QMS-FRM-821, to reference an ISSUE ID (ISSUE ID group the complaints based on the causes of the complaints); and 4) to update the Feedback and Complaint Work Instruction, QMS-WRK-821, to describe the process of grouping a new complaint to an existing ISSUE ID in order to determine if an investigation is necessary. Without all of the aforementioned supporting evidence, the evidence needed to evaluate the adequacy of this response is incomplete.\n\nOur office requests that your firm, Trexo Robotics Holdings Inc., cease any activities that result in the misbranding or adulteration of the Trexo devices, such as the commercial distribution of the devices for the uses discussed above.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to: CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the identification number CMS #673150 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Heather Dean, Ph.D., Assistant Director, Physical Medicine-Acute Injury Devices Team at (240) 402-9874.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCAPT Nina Mezu-Nwaba, PharmD., MPH., MSc.\n\nDeputy Director\n\nOHT5: Office of Neurological\n\nand Physical Medicine Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Trexo Robotics Holdings Inc.","trexo-robotics-holdings-inc-673150-02072024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrexo-robotics-holdings-inc-673150-02072024","2026-10-26T08:10:14.765948+00:00","2024-06-04","673150","Medical Devices","\"OHT5: Office of Neurological and Physical Medicine Devices, Office of Product Evaluation and Quality\"","Manmeet Maggu","2026-08-20T00:03:38.973+00:00","VIA Electronic Mail","2024-02-07",{"id":169,"raw":170,"subject":174,"body_html":175,"body_text":176,"firm_name":177,"letter_id":178,"created_at":67,"fei_number":20,"letter_url":179,"updated_at":180,"action_type":23,"case_status":24,"posted_date":181,"marcs_cms_no":182,"product_type":27,"closeout_date":20,"issuing_office":130,"recipient_name":183,"body_fetched_at":184,"delivery_method":122,"recipient_title":20,"reference_number":185,"action_taken_date":186,"medical_device_id":20,"response_letter_date":20},1001,[171,172,173,130,174,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-24T05:00:00Z\">02\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-pharmacare-holdings-limited-701671-02242025\">Aspen Pharmacare Holdings Limited\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-46\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stephen Saad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group Chief Executive  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aspen Pharmacare Holdings Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9 Rydall Vale Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Douglas Saunders Drive, La Lucia Ridge\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Durban\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KwaZulu-Natal\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>4051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Africa\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:SSaad@aspenpharma\"> SSaad@aspenpharma\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-46\u003C\u002Fp>\u003Cp>February 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Saad:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aspen SA Sterile Operations (Pty) Ltd. (an Aspen Pharmacare Holdings Limited subsidiary), FEI 3007490529, at 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020, from September 9 to 17, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 8, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not establish appropriate specifications or test your sterile over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products to monitor impurities at release and throughout expiry. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You did not perform impurity testing prior to release and during stability for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>You did not establish scientifically justified specifications to monitor impurities during stability testing of drug products containing Naphazoline Hydrochloride or Tetrahydrozoline Hydrochloride active pharmaceutical ingredient (API).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that the impurity limits were established based on your customer’s requirements and that no limits were included for release testing. You provide your customer’s health hazard evaluation (HHE) which concluded that the presence of Impurity \u003Cstrong>(b)(4)\u003C\u002Fstrong> at stability levels of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> content would not pose any safety risk for those that use the products according to directions. The Agency disagrees with the HHE assessment and concludes that the presence of impurity levels at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% may pose a risk to patient safety at the recommended dosage. It is your responsibility to ensure that appropriate specifications are established to monitor impurities throughout the expiry period.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack adequate scientific rationale for the current impurity specifications of your drug products. A similar deficiency for the lack of impurity specifications for release and stability testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> API containing products was also identified during the 2016 inspection. However, this deficiency has not been fully addressed to date. Additionally, your risk assessment does not include an evaluation of reserve samples of potentially impacted product batches distributed to the United States.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Insufficient release and stability testing to appropriately detect impurities in your drug products could potentially impact product quality and patient safety.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Degradation study protocols and reports for your drug products, which should include impurities that will be monitored throughout the product life cycle as well as your scientific justification for the acceptance criteria and study design.\u003C\u002Fli>\u003Cli>A list of current and revised specifications for release and stability testing, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. These poor practices included, but were not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Operators blocked first air by placing their gloved hands directly over open sterilized bottles without clearing them from the aseptic filling line.\u003C\u002Fli>\u003Cli>Operators used their gloved hands instead of using appropriate sterile tools to remove jammed bottles.\u003C\u002Fli>\u003Cli>Operator movements in the critical areas were not always slow and deliberate.\u003C\u002Fli>\u003Cli>Operators used goggles that had numerous open holes and therefore had exposed skin during line set-up and aseptic processing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In 2022, your firm identified contamination in two media fill batches one on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line and another on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line. You identified the root cause as poor aseptic behavior. These contamination events along with the poor aseptic practices observed during our inspection indicate your aseptic manufacturing operations may lack adequate control. Your firm did not perform a sufficiently comprehensive evaluation of aseptic behavior of operators as part of this recurrent trend.\u003C\u002Fp>\u003Cp>We also note that open door interventions required a large door to be opened. On numerous occasions, the door remained opened for extended periods of time while the line was still in-operation. When opened, the door was exposed to the ISO 7 area, and when being closed, there was a significant risk of the lower quality room air sweeping into the ISO 5 aseptic processing area. Empty sterile containers were located extremely close to the door. In addition, operators did not adequately disinfect the open door. While spraying disinfectant on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, operators failed to consider open sterilized bottles on the line, exposing them to potential contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Studies and Cleanroom Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your smoke studies did not adequately demonstrate unidirectional air flow in the ISO 5 classified areas used for the aseptic filling of ophthalmic drug products on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling lines. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your smoke studies lacked simulation of aseptic line set-up, dynamic operations, and interventions that occur during aseptic manufacturing operations.\u003C\u002Fli>\u003Cli>Generation of smoke was not sufficient to demonstrate unidirectional air flow.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We also note that there were multiple aspects of your cleanroom and aseptic processing line design which represented fundamental contamination risks:\u003C\u002Fp>\u003Cul>\u003Cli>There was no physical barrier between the operator and the open \u003Cstrong>(b)(4)\u003C\u002Fstrong>-sterilized bottles on the conveyor. Your production operator remained inside the ISO 5 aseptic processing area, sitting or standing next to the conveyor line where open, exposed bottles pass.\u003C\u002Fli>\u003Cli>There were extensive manual interactions with the aseptic processing line and its exposed sterile drug product and containers\u002Fclosures.\u003C\u002Fli>\u003Cli>Operators performed multiple manual interventions during filling by \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> not being installed on these \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These interventions may pose inherent risks to your aseptic processes.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The ISO 5 area is critical because sterile product is exposed and therefore vulnerable to contamination. Your aseptic filling process should be designed, and operations executed, to prevent contamination hazards to your sterile product. The flawed design of the filling line and execution of the aseptic operations promote influx of contamination into the critical filling areas.\u003C\u002Fp>\u003Cp>In your response, you indicate that you temporarily suspended manufacturing on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line. You acknowledge that the design of your aseptic filling lines is not optimal and indicate that an independent review of your design and remediation plans for both “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling lines will be performed. You also commit to perform new smoke studies under static and dynamic conditions and evaluate associated risks. You indicate that you have engaged a third-party consultant to assist in improving aseptic practices.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not sufficiently address the lack of oversight of aseptic behavior of operators. Further, you do not adequately investigate poor aseptic practices to determine the impact on sterile drug products manufactured and aseptic processing areas. You also do not clearly specify how you will improve your smoke studies, including what interventions will be included, and how you will address potential deficiencies.\u003C\u002Fp>\u003Cp>For additional guidance on aseptic processing see FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fli>\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and suitability, including ergonomics for each human interaction.\u003Cbr>o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>o Reduction or elimination of aseptic manipulations and connections (e.g., replacing post-filtration aseptic connections with sterilize-in-place system)\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Smoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release. Your operators obtained and printed a passing result after multiple production filter integrity tests failed. Your operators did not record or print the failing results. For example:\u003C\u002Fp>\u003Cul>\u003Cli>On August 8, 2024, two operators performed four post-use sterilizing filter integrity tests for \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The four tests included three failing results and the final passing result. Your operators only reported the passing result.\u003C\u002Fli>\u003Cli>On July 25, 2024, two operators performed nine filter integrity tests associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, bulk batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The nine tests included five failing results, three aborted tests, and the final passing result. Your operators only reported the passing result.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you acknowledge the deficiency and commit to perform a full audit trail review of your production equipment. You also indicate that you are completing the investigations into anomalous filter integrity tests.\u003C\u002Fp>\u003Cp>Your response is inadequate as you do not provide details of the investigation outcome or explain whether effective corrective actions and preventive actions (CAPAs) have been implemented. Further, you do not provide the scope and time period of the retrospective review to ensure all batches potentially affected are part of the assessment.\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003Cbr>o A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>o A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including manufacturing records.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Ensure that appropriate procedures are in place regarding the review of all critical electronic data (e.g., filter integrity testing).\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You did not establish an adequate system for monitoring environmental conditions on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ aseptic filling line. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You did not conduct viable monitoring of the air and surfaces in ISO 5 areas where an operator was continuously present removing fallen bottles.\u003C\u002Fli>\u003Cli>You did not place the non-viable particle monitoring (NVPM) probes in representative ISO 5 areas where the product and primary components were exposed. Our investigators noted the following:\u003Cbr>o The NVPM probe closest to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was located approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> above the level of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o The NVPM probe nearest to the sterile cap \u003Cstrong>(b)(4)\u003C\u002Fstrong> was located approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> above the level of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Your operators routinely placed mobile NVPM devices in locations different from those specified in your procedures to monitor the ISO 5 areas. As such, NVPM data may not accurately represent the critical areas in operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to upgrade your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line and perform a Quality Risk Assessment for NVPM in Suite \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you commit to conducting a Quality Risk Assessment for NVPM to identify, assess, and mitigate all gaps, you have not provided any updates on the status of risk assessment. Vigilant and responsive environmental monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A thorough, independent assessment, and CAPA for your environmental monitoring program. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention, and overall environmental control in your assessment.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>An independent, retrospective evaluation of all ISO 5 NVPM deviations, root causes, and a relevant CAPA plan.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. You are responsible for ensuring consultants you use are qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements and to correct repeat violations. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs for the U.S. market.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert (IA) 66-40 on February 10, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Aspen SA Sterile Operations (Pty) Ltd., 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020 into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. We request you email CDER-OC-OMQ-Communications@fda.hhs.gov, within 5 days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007490529 and ATTN: Anita Narula, Ph.D.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-46\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Stephen Saad\n\nRecipient Title\n\nGroup Chief Executive\n\nAspen Pharmacare Holdings Limited\n\n9 Rydall Vale Park\n\nDouglas Saunders Drive, La Lucia Ridge\n\nDurban\n\nKwaZulu-Natal\n\n4051\n\nSouth Africa\n\nSSaad@aspenpharma\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-46\nFebruary 24, 2025\nDear Mr. Saad:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aspen SA Sterile Operations (Pty) Ltd. (an Aspen Pharmacare Holdings Limited subsidiary), FEI 3007490529, at 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020, from September 9 to 17, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 8, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour firm did not establish appropriate specifications or test your sterile over-the-counter (OTC) (b)(4) drug products to monitor impurities at release and throughout expiry. For example:\nYou did not perform impurity testing prior to release and during stability for (b)(4).\nYou did not establish scientifically justified specifications to monitor impurities during stability testing of drug products containing Naphazoline Hydrochloride or Tetrahydrozoline Hydrochloride active pharmaceutical ingredient (API).\nIn your response, you state that the impurity limits were established based on your customer’s requirements and that no limits were included for release testing. You provide your customer’s health hazard evaluation (HHE) which concluded that the presence of Impurity (b)(4) at stability levels of up to (b)(4)% of the labeled (b)(4) content would not pose any safety risk for those that use the products according to directions. The Agency disagrees with the HHE assessment and concludes that the presence of impurity levels at (b)(4)% may pose a risk to patient safety at the recommended dosage. It is your responsibility to ensure that appropriate specifications are established to monitor impurities throughout the expiry period.\nYour response is inadequate. You lack adequate scientific rationale for the current impurity specifications of your drug products. A similar deficiency for the lack of impurity specifications for release and stability testing for (b)(4) API containing products was also identified during the 2016 inspection. However, this deficiency has not been fully addressed to date. Additionally, your risk assessment does not include an evaluation of reserve samples of potentially impacted product batches distributed to the United States.\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Insufficient release and stability testing to appropriately detect impurities in your drug products could potentially impact product quality and patient safety.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nDegradation study protocols and reports for your drug products, which should include impurities that will be monitored throughout the product life cycle as well as your scientific justification for the acceptance criteria and study design.\nA list of current and revised specifications for release and stability testing, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Practices\nDuring the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile (b)(4) drug products. These poor practices included, but were not limited to:\nOperators blocked first air by placing their gloved hands directly over open sterilized bottles without clearing them from the aseptic filling line.\nOperators used their gloved hands instead of using appropriate sterile tools to remove jammed bottles.\nOperator movements in the critical areas were not always slow and deliberate.\nOperators used goggles that had numerous open holes and therefore had exposed skin during line set-up and aseptic processing.\nIn 2022, your firm identified contamination in two media fill batches one on the “(b)(4)” aseptic filling line and another on the “(b)(4)” aseptic filling line. You identified the root cause as poor aseptic behavior. These contamination events along with the poor aseptic practices observed during our inspection indicate your aseptic manufacturing operations may lack adequate control. Your firm did not perform a sufficiently comprehensive evaluation of aseptic behavior of operators as part of this recurrent trend.\nWe also note that open door interventions required a large door to be opened. On numerous occasions, the door remained opened for extended periods of time while the line was still in-operation. When opened, the door was exposed to the ISO 7 area, and when being closed, there was a significant risk of the lower quality room air sweeping into the ISO 5 aseptic processing area. Empty sterile containers were located extremely close to the door. In addition, operators did not adequately disinfect the open door. While spraying disinfectant on the (b)(4), operators failed to consider open sterilized bottles on the line, exposing them to potential contamination.\nInadequate Smoke Studies and Cleanroom Design\nYour smoke studies did not adequately demonstrate unidirectional air flow in the ISO 5 classified areas used for the aseptic filling of ophthalmic drug products on the “(b)(4)” and “(b)(4)” aseptic filling lines. For example:\nYour smoke studies lacked simulation of aseptic line set-up, dynamic operations, and interventions that occur during aseptic manufacturing operations.\nGeneration of smoke was not sufficient to demonstrate unidirectional air flow.\nWe also note that there were multiple aspects of your cleanroom and aseptic processing line design which represented fundamental contamination risks:\nThere was no physical barrier between the operator and the open (b)(4)-sterilized bottles on the conveyor. Your production operator remained inside the ISO 5 aseptic processing area, sitting or standing next to the conveyor line where open, exposed bottles pass.\nThere were extensive manual interactions with the aseptic processing line and its exposed sterile drug product and containers\u002Fclosures.\nOperators performed multiple manual interventions during filling by (b)(4) or (b)(4) due to (b)(4) not being installed on these (b)(4). These interventions may pose inherent risks to your aseptic processes.\nThe ISO 5 area is critical because sterile product is exposed and therefore vulnerable to contamination. Your aseptic filling process should be designed, and operations executed, to prevent contamination hazards to your sterile product. The flawed design of the filling line and execution of the aseptic operations promote influx of contamination into the critical filling areas.\nIn your response, you indicate that you temporarily suspended manufacturing on the “(b)(4)” aseptic filling line. You acknowledge that the design of your aseptic filling lines is not optimal and indicate that an independent review of your design and remediation plans for both “(b)(4)” and “(b)(4)” aseptic filling lines will be performed. You also commit to perform new smoke studies under static and dynamic conditions and evaluate associated risks. You indicate that you have engaged a third-party consultant to assist in improving aseptic practices.\nYour response is inadequate because it does not sufficiently address the lack of oversight of aseptic behavior of operators. Further, you do not adequately investigate poor aseptic practices to determine the impact on sterile drug products manufactured and aseptic processing areas. You also do not clearly specify how you will improve your smoke studies, including what interventions will be included, and how you will address potential deficiencies.\nFor additional guidance on aseptic processing see FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and suitability, including ergonomics for each human interaction.\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\no Reduction or elimination of aseptic manipulations and connections (e.g., replacing post-filtration aseptic connections with sterilize-in-place system)\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nSmoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\n3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\nYour Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release. Your operators obtained and printed a passing result after multiple production filter integrity tests failed. Your operators did not record or print the failing results. For example:\nOn August 8, 2024, two operators performed four post-use sterilizing filter integrity tests for (b)(4) batch (b)(4). The four tests included three failing results and the final passing result. Your operators only reported the passing result.\nOn July 25, 2024, two operators performed nine filter integrity tests associated with (b)(4), bulk batch (b)(4). The nine tests included five failing results, three aborted tests, and the final passing result. Your operators only reported the passing result.\nIn your response, you acknowledge the deficiency and commit to perform a full audit trail review of your production equipment. You also indicate that you are completing the investigations into anomalous filter integrity tests.\nYour response is inadequate as you do not provide details of the investigation outcome or explain whether effective corrective actions and preventive actions (CAPAs) have been implemented. Further, you do not provide the scope and time period of the retrospective review to ensure all batches potentially affected are part of the assessment.\nSee FDA’s guidance document, Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\no A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\no A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including manufacturing records.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Ensure that appropriate procedures are in place regarding the review of all critical electronic data (e.g., filter integrity testing).\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\nYou did not establish an adequate system for monitoring environmental conditions on the “(b)(4)’ aseptic filling line. For example:\nYou did not conduct viable monitoring of the air and surfaces in ISO 5 areas where an operator was continuously present removing fallen bottles.\nYou did not place the non-viable particle monitoring (NVPM) probes in representative ISO 5 areas where the product and primary components were exposed. Our investigators noted the following:\no The NVPM probe closest to the (b)(4) was located approximately (b)(4) above the level of the (b)(4).\no The NVPM probe nearest to the sterile cap (b)(4) was located approximately (b)(4) above the level of the (b)(4).\nYour operators routinely placed mobile NVPM devices in locations different from those specified in your procedures to monitor the ISO 5 areas. As such, NVPM data may not accurately represent the critical areas in operation.\nIn your response, you commit to upgrade your “(b)(4)” aseptic filling line and perform a Quality Risk Assessment for NVPM in Suite (b)(4).\nYour response is inadequate. While you commit to conducting a Quality Risk Assessment for NVPM to identify, assess, and mitigate all gaps, you have not provided any updates on the status of risk assessment. Vigilant and responsive environmental monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\nIn response to this letter, provide:\nA thorough, independent assessment, and CAPA for your environmental monitoring program. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention, and overall environmental control in your assessment.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nAn independent, retrospective evaluation of all ISO 5 NVPM deviations, root causes, and a relevant CAPA plan.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nCGMP Consultant Recommended\nWe acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. You are responsible for ensuring consultants you use are qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements and to correct repeat violations. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs for the U.S. market.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed products offered for import into the United States from your firm on Import Alert (IA) 66-40 on February 10, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Aspen SA Sterile Operations (Pty) Ltd., 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020 into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. We request you email CDER-OC-OMQ-Communications@fda.hhs.gov, within 5 days of receipt of this letter to schedule a regulatory meeting.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007490529 and ATTN: Anita Narula, Ph.D.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Aspen Pharmacare Holdings Limited","aspen-pharmacare-holdings-limited-701671-02242025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-pharmacare-holdings-limited-701671-02242025","2026-10-26T08:07:58.529819+00:00","2025-03-18","701671","Mr. Stephen Saad","2026-08-19T16:56:02.725+00:00","320-25-46","2025-02-24",{"id":188,"raw":189,"subject":39,"body_html":193,"body_text":194,"firm_name":195,"letter_id":196,"created_at":67,"fei_number":20,"letter_url":197,"updated_at":198,"action_type":23,"case_status":24,"posted_date":199,"marcs_cms_no":200,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":201,"body_fetched_at":202,"delivery_method":52,"recipient_title":20,"reference_number":203,"action_taken_date":204,"medical_device_id":20,"response_letter_date":20},1496,[190,191,192,38,39,13,13,13],"\u003Ctime datetime=\"2024-05-01T13:00:00Z\">05\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-30T04:00:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frpf-swedish-holdings-llc-dba-puffsee-682389-04302024\">RPF Swedish Holdings LLC d\u002Fb\u002Fa Puffsee\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402143\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Josefin E. Klasson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>RPF Swedish Holdings LLC d\u002Fb\u002Fa Puffsee\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4450 Newton Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92113-3433\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@puffsee.com\"> contact@puffsee.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:josefineklasson@hotmail.com\"> josefineklasson@hotmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 30, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Josefin E. Klasson:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fpuffsee.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Kangvape Onee Max, Sour Apple Ice; and EBDesign TE6000 Autumn.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402143, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Atencio\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Contact Privacy Inc. Customer 0166708750\u003Cbr>\npuffsee.com@contactprivacy.com\u003C\u002Fp>\n\n\u003Cp>Tucows Domains Inc.\u003Cbr>\ndomainabuse@tucows.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402143\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJosefin E. Klasson\n\nRPF Swedish Holdings LLC d\u002Fb\u002Fa Puffsee\n\n4450 Newton Ave.\n\nSan Diego, CA 92113-3433\n\nUnited States\n\ncontact@puffsee.com\n\njosefineklasson@hotmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 30, 2024\n\nWARNING LETTER\n\nDear Josefin E. Klasson:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fpuffsee.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Kangvape Onee Max, Sour Apple Ice; and EBDesign TE6000 Autumn.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402143, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Atencio\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nContact Privacy Inc. Customer 0166708750\n\npuffsee.com@contactprivacy.com\n\nTucows Domains Inc.\n\ndomainabuse@tucows.com\n\nShopify, Inc.\n\nabuse@shopify.com","RPF Swedish Holdings LLC d\u002Fb\u002Fa Puffsee","rpf-swedish-holdings-llc-dba-puffsee-682389-04302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frpf-swedish-holdings-llc-dba-puffsee-682389-04302024","2026-10-26T08:09:51.569225+00:00","2024-05-01","682389","Josefin E. Klasson","2026-08-20T00:08:33.68+00:00","RW2402143","2024-04-30",{"id":206,"raw":207,"subject":39,"body_html":211,"body_text":212,"firm_name":213,"letter_id":214,"created_at":215,"fei_number":20,"letter_url":216,"updated_at":217,"action_type":23,"case_status":24,"posted_date":218,"marcs_cms_no":219,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":220,"body_fetched_at":221,"delivery_method":52,"recipient_title":20,"reference_number":20,"action_taken_date":218,"medical_device_id":20,"response_letter_date":20},3022,[208,209,210,38,39,13,13,13],"\u003Ctime datetime=\"2021-11-17T20:00:00Z\">11\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-17T05:00:00Z\">11\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdfw-vapor-holdings-inc-dba-vapor-lakes-inc-620297-11172021\">DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Bosse\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Brand Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>720 Valley Ridge Circle, Suite #4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lewisville\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75057\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:brendanl@vaporlakes.com\"> brendanl@vaporlakes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 17, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bosse:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your&nbsp;submissions to the FDA and our inspection records, and determined DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at&nbsp;\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: VAPOR LAKES Blueberry 3MG\u002F30ML, VAPOR LAKES Lemonade 3MG\u002F30ML, and VAPOR LAKES Strawdairy 3MG\u002F30ML.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 14,500 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs), assigned STNs PM0003453, PM0003786, and PM0003530 on September 8, 2020 and September 9, 2020. However, FDA issued a negative action for STNs PM0003453, PM0003530, and PM0003786 in the form of a Marketing Denial Order determination on September 8, 2021, which covers 380 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STNs PM0003453, PM0003530, and PM0003786 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100329, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJames Bosse\n\nRecipient Title\n\nBrand Owner\n\nDFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.\n\n720 Valley Ridge Circle, Suite #4\n\nLewisville, TX 75057\n\nUnited States\n\nbrendanl@vaporlakes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 17, 2021\n\nWARNING LETTER\n\nDear Mr. Bosse:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc. manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: VAPOR LAKES Blueberry 3MG\u002F30ML, VAPOR LAKES Lemonade 3MG\u002F30ML, and VAPOR LAKES Strawdairy 3MG\u002F30ML.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 14,500 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs), assigned STNs PM0003453, PM0003786, and PM0003530 on September 8, 2020 and September 9, 2020. However, FDA issued a negative action for STNs PM0003453, PM0003530, and PM0003786 in the form of a Marketing Denial Order determination on September 8, 2021, which covers 380 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STNs PM0003453, PM0003530, and PM0003786 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100329, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","DFW Vapor Holdings Inc. d\u002Fb\u002Fa Vapor Lakes, Inc.","dfw-vapor-holdings-inc-dba-vapor-lakes-inc-620297-11172021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdfw-vapor-holdings-inc-dba-vapor-lakes-inc-620297-11172021","2026-10-26T08:08:24.07184+00:00","2021-11-17","620297","James Bosse","2026-08-20T02:26:09.107+00:00",{"id":223,"raw":224,"subject":39,"body_html":228,"body_text":229,"firm_name":230,"letter_id":231,"created_at":215,"fei_number":20,"letter_url":232,"updated_at":233,"action_type":23,"case_status":24,"posted_date":234,"marcs_cms_no":235,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":236,"body_fetched_at":237,"delivery_method":52,"recipient_title":20,"reference_number":20,"action_taken_date":234,"medical_device_id":20,"response_letter_date":20},3072,[225,226,227,38,39,13,13,13],"\u003Ctime datetime=\"2021-10-21T19:00:00Z\">10\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-21T04:00:00Z\">10\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmj-asset-holdings-llc-dba-marcos-vapor-619143-10212021\">MJ Asset Holdings, LLC d\u002Fb\u002Fa Marco&#039;s Vapor\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marco G. Altamore\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MJ Asset Holdings, LLC d\u002Fb\u002Fa Marco's Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1957 Pawlisch Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rockford\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>61112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:marco95altamore@gmail.com\"> marco95altamore@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Altamore:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that MJ Asset Holdings, LLC d\u002Fb\u002Fa Marco's Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Custom Clouds NERDZ 03mg\u002FmL 60 mL, Custom Clouds WHITE FOX 1.5 mg\u002FmL 60 mL, Custom Clouds TIGER’S BLOOD 1.5mg\u002FmL 60 mL, Custom Clouds SKYWALKER 06mg\u002FmL 60 mL, and Custom Clouds CANYON 03mg\u002FmL 120 mL.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002311, on September 9, 2020. However, FDA issued a negative action for STN PM0002311 in the form of a Marketing Denial Order determination on September 3, 2021, which covers 5,950 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002311 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003Cbr>\n\u003Cbr>\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100268, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc: marco99altamore@gmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMarco G. Altamore\n\nRecipient Title\n\nOwner\n\nMJ Asset Holdings, LLC d\u002Fb\u002Fa Marco's Vapor\n\n1957 Pawlisch Drive\n\nRockford, IL 61112\n\nUnited States\n\nmarco95altamore@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Altamore:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that MJ Asset Holdings, LLC d\u002Fb\u002Fa Marco's Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Custom Clouds NERDZ 03mg\u002FmL 60 mL, Custom Clouds WHITE FOX 1.5 mg\u002FmL 60 mL, Custom Clouds TIGER’S BLOOD 1.5mg\u002FmL 60 mL, Custom Clouds SKYWALKER 06mg\u002FmL 60 mL, and Custom Clouds CANYON 03mg\u002FmL 120 mL.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002311, on September 9, 2020. However, FDA issued a negative action for STN PM0002311 in the form of a Marketing Denial Order determination on September 3, 2021, which covers 5,950 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002311 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100268, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc: marco99altamore@gmail.com","MJ Asset Holdings, LLC d\u002Fb\u002Fa Marco's Vapor","mj-asset-holdings-llc-dba-marcos-vapor-619143-10212021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmj-asset-holdings-llc-dba-marcos-vapor-619143-10212021","2026-10-26T08:09:26.551504+00:00","2021-10-21","619143","Marco G. Altamore","2026-08-20T02:30:23.343+00:00",{"id":239,"raw":240,"subject":39,"body_html":244,"body_text":245,"firm_name":246,"letter_id":247,"created_at":44,"fei_number":20,"letter_url":248,"updated_at":249,"action_type":23,"case_status":24,"posted_date":250,"marcs_cms_no":251,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":252,"body_fetched_at":253,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":250,"medical_device_id":20,"response_letter_date":20},2079,[241,242,243,38,39,13,13,13],"\u003Ctime datetime=\"2023-05-31T13:20:00Z\">05\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-31T04:00:00Z\">05\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjtbc-holdings-llc-dba-disposable305-657236-05312023\">JTBC Holdings LLC d\u002Fb\u002Fa Disposable305\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph J Benhamu Cohen and Tamar R. Benhamu Cohen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>JTBC Holdings LLC d\u002Fb\u002Fa Disposable305\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>19532 Diplomat Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33179-6439\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:305disposable@gmail.com\"> 305disposable@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:josephbenhamu@gmail.com\"> josephbenhamu@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 31, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Joseph J Benhamu Cohen and Tamar R. Benhamu Cohen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthedisposablevapes.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fthedisposablevapes.com revealed that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Puff Plus – Orange Soda and Puff Plus – Aloe Grape.\u003C\u002Fp>\n\n\u003Cp>These ENDS products are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&amp;C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301933, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>JTBC Holdings LLC dba Disposable305\u003Cbr>\nAttn: Joseph J Benhamu Cohen\u003Cbr>\n3625 Pembroke Rd.\u003Cbr>\nHollywood, FL 33021\u003C\u002Fp>\n\n\u003Cp>JTBC Holdings LLC dba Disposable305\u003Cbr>\nAttn: Joseph J Benhamu Cohen\u003Cbr>\n2012 NE St.\u003Cbr>\nNorth Miami Beach, FL 33162\u003C\u002Fp>\n\n\u003Cp>JTBC Holdings LLC dba Disposable305\u003Cbr>\nAttn: Sharon Benalloun\u003Cbr>\n20281 E. Country Club Dr. 1405\u003Cbr>\nAventura, FL 33180\u003C\u002Fp>\n\n\u003Cp>Contact Privacy Inc. Customer 0158488091\u003Cbr>\nthedisposablevapes.com@contactprivacy.com\u003C\u002Fp>\n\n\u003Cp>Tucows Domains Inc.\u003Cbr>\ndomainabuse@tucows.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJoseph J Benhamu Cohen and Tamar R. Benhamu Cohen\n\nJTBC Holdings LLC d\u002Fb\u002Fa Disposable305\n\n19532 Diplomat Dr\n\nMiami, FL 33179-6439\n\nUnited States\n\n305disposable@gmail.com\n\njosephbenhamu@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 31, 2023\n\nWARNING LETTER\n\nDear Joseph J Benhamu Cohen and Tamar R. Benhamu Cohen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthedisposablevapes.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fthedisposablevapes.com revealed that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Puff Plus – Orange Soda and Puff Plus – Aloe Grape.\n\nThese ENDS products are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&C Act. It is your responsibility to ensure that these tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory or legal action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301933, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nJTBC Holdings LLC dba Disposable305\n\nAttn: Joseph J Benhamu Cohen\n\n3625 Pembroke Rd.\n\nHollywood, FL 33021\n\nJTBC Holdings LLC dba Disposable305\n\nAttn: Joseph J Benhamu Cohen\n\n2012 NE St.\n\nNorth Miami Beach, FL 33162\n\nJTBC Holdings LLC dba Disposable305\n\nAttn: Sharon Benalloun\n\n20281 E. Country Club Dr. 1405\n\nAventura, FL 33180\n\nContact Privacy Inc. Customer 0158488091\n\nthedisposablevapes.com@contactprivacy.com\n\nTucows Domains Inc.\n\ndomainabuse@tucows.com\n\nShopify, Inc.\n\nabuse@shopify.com","JTBC Holdings LLC d\u002Fb\u002Fa Disposable305","jtbc-holdings-llc-dba-disposable305-657236-05312023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjtbc-holdings-llc-dba-disposable305-657236-05312023","2026-10-26T08:09:05.975224+00:00","2023-05-31","657236","Joseph J Benhamu Cohen and Tamar R. Benhamu Cohen","2026-08-20T01:04:44.506+00:00",{"id":255,"raw":256,"subject":39,"body_html":260,"body_text":261,"firm_name":262,"letter_id":263,"created_at":90,"fei_number":20,"letter_url":264,"updated_at":265,"action_type":23,"case_status":24,"posted_date":266,"marcs_cms_no":267,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":20,"body_fetched_at":268,"delivery_method":52,"recipient_title":20,"reference_number":269,"action_taken_date":270,"medical_device_id":20,"response_letter_date":20},763,[257,258,259,38,39,13,13,13],"\u003Ctime datetime=\"2025-07-18T04:00:00Z\">07\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-17T04:00:00Z\">07\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famv-holdings-dba-kure-cbd-and-vape-712004-07172025\">AMV Holdings, d\u002Fb\u002Fa Kure CBD and Vape\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501256\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>AMV Holdings, d\u002Fb\u002Fa Kure CBD and Vape\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9211 North Tryon Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Charlotte\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>28262\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that AMV Holdings, d\u002Fb\u002Fa Kure CBD and Vape sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: Innevape HEISENBERG MENTHOL ORIGINAL BLUE SLUSHIE 6mg 100ml.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501256, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501256\n\nProduct:\n\nTobacco\n\nRecipient:\n\nAMV Holdings, d\u002Fb\u002Fa Kure CBD and Vape\n\n9211 North Tryon Street\n\nCharlotte, NC 28262\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJuly 17, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that AMV Holdings, d\u002Fb\u002Fa Kure CBD and Vape sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following e-liquid products that lack a marketing authorization order: Innevape HEISENBERG MENTHOL ORIGINAL BLUE SLUSHIE 6mg 100ml.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501256, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","AMV Holdings, d\u002Fb\u002Fa Kure CBD and Vape","amv-holdings-dba-kure-cbd-and-vape-712004-07172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famv-holdings-dba-kure-cbd-and-vape-712004-07172025","2026-10-26T08:07:55.648894+00:00","2025-07-18","712004","2026-08-19T16:34:36.808+00:00","ER2501256","2025-07-17",{"id":272,"raw":273,"subject":174,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":67,"fei_number":20,"letter_url":281,"updated_at":282,"action_type":23,"case_status":24,"posted_date":283,"marcs_cms_no":284,"product_type":27,"closeout_date":20,"issuing_office":130,"recipient_name":285,"body_fetched_at":286,"delivery_method":143,"recipient_title":20,"reference_number":287,"action_taken_date":288,"medical_device_id":20,"response_letter_date":20},1056,[274,275,276,130,174,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-29T05:00:00Z\">01\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famwiner-raphe-holdings-llc-dba-raphegenerics-corp-698782-01292025\">AmWiner &amp; Raphe Holdings, LLC  dba rapheGenerics Corp \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-36\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Ijyahu Raphe Eze\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AmWiner &amp; Raphe Holdings, LLC  dba rapheGenerics Corp \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>802 East Walnut Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Garland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-36\u003C\u002Fp>\u003Cp>January 29, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Eze:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, AmWiner &amp; Raphe Holdings LLC, FEI 3009569638, at 11601 Plano Road Suite 104, Dallas, Texas 75243, from June 20 to August 7, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your August 21, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures topical over-the-counter (OTC) drug products, including drug products that contain the active ingredient minoxidil. You failed to establish adequate release testing procedures or specifications for your OTC drug products, and accordingly released batches of drug products for distribution without conducting adequate testing to confirm critical quality attributes.\u003C\u002Fp>\u003Cp>In your response, you state that your finished product testing will be performed by a contract laboratory. Your response is inadequate. You did not describe how you will ensure that your finished products meet appropriate quality standards prior to release. You also did not consider a detailed risk assessment addressing the potential effects of releasing drug product to the market without established specifications to ensure their identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to complete equipment and process performance qualification (PPQ) prior to releasing your OTC drug products. Likewise, you lacked appropriate documentation, qualification, maintenance, and monitoring of your purified water system, which is used in the manufacture of your OTC drug products.\u003C\u002Fp>\u003Cp>In your response, you state that procedures have been established to monitor and validate the performance of your manufacturing processes including qualifying all manufacturing equipment. You also commit to testing your purified water before it used in any manufacturing process.\u003C\u002Fp>\u003Cp>Your response is inadequate as you did not provide sufficient information (such as validation protocols, reports, or timelines) to establish that your equipment and processes are adequately qualified and validated. Further, information, such as sampling procedures, testing procedures, method validation, or routine monitoring results, were not provided to support that your purified water system is adequately monitored and maintained.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for PPQ and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system.\u003Cbr>o A purified water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your purified water system. Ensure that the total count limits for your purified water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets Purified Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming components, including propylene glycol and active ingredients such as minoxidil, for identity before using them in the manufacture of your OTC drug products. Additionally, you relied on your suppliers’ certificates of analysis (COAs) without establishing the reliability of each of your suppliers’ analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Propylene Glycol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of propylene glycol for identity, components at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. Identity testing for glycerin, propylene glycol, and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug product.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that “full compendial” testing of raw materials will be performed by a contract laboratory. You also state that propylene glycol will be tested for DEG impurities before use in manufacturing, and that your firm will no longer depend on the manufacturer's COA for propylene glycol and minoxidil. Your response is inadequate. You did not provide a detailed plan for how components will be tested, including test methods and review of compendial requirements, or a timeline for implementing the corrective actions proposed. Additionally, you did not describe how you plan to establish the reliability of the test results on your suppliers’ COAs at appropriate intervals. Further, you did not consider testing retains of raw materials or a retrospective review of previously distributed OTC drug products.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product lots for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, propylene glycol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical and microbiology quality control specifications you use to test each incoming lot of each incoming lot of components, including, high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH\u003C\u002Fu>”\u003C\u002Fp>\u003Cul>\u003Cli>“HAIR REGROWTH TREATMENT EXTRA STRENGTH” [from the product label]\u003C\u002Fli>\u003Cli>“\u003Cstrong>Uses\u003C\u002Fstrong> · Relieves scalp itching, irritation, redness, flaking and scaling due to seborrheic dermatitis · Helps eliminate recurrence of seborrheic dermatitis” [from the product label]\u003C\u002Fli>\u003Cli>“Help hair loss and regrow fuller hair with LifeCell Extra Strength Hair Regrowth Treatment. This fast-working hair loss treatment is clinically proven to regrow up to 25% more hair. Unlike hair loss shampoos and hair thickening products that temporarily plump hair from the outside, LifeCell penetrates the scalp to reactivate shrunken hair follicles. The Minoxidil formula works to boost hair follicle activity and hair protein production, allowing for regrowth of hair. This hair thinning treatment comes in a topical solution that is easy to use: Simply apply 1 milliliter directly to your scalp twice daily and massage it through your hair.” [from the product website https:\u002F\u002Fwww.lifecellskin.com\u002F]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“\u003Cu>WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT\u003C\u002Fu>”\u003C\u002Fp>\u003Cul>\u003Cli>“HAIR REGROWTH TREATMENT” [from the product label]\u003C\u002Fli>\u003Cli>“Reactivates Hair Follicles To Stimulate Regrowth” [from the product label]\u003C\u002Fli>\u003Cli>“\u003Cstrong>Uses\u003C\u002Fstrong> · Relieves scalp itching, irritation, redness, flaking and scaling due to seborrheic dermatitis · Helps eliminate recurrence of seborrheic dermatitis” [from the product label]\u003C\u002Fli>\u003Cli>“Help hair loss and regrow fuller hair with LifeCell Extra Strength Hair Regrowth Treatment. This fast-working hair loss treatment is clinically proven to regrow up to 25% more hair. Unlike hair loss shampoos and hair thickening products that temporarily plump hair from the outside, LifeCell penetrates the scalp to reactivate shrunken hair follicles. The Minoxidil formula works to boost hair follicle activity and hair protein production, allowing for regrowth of hair. This hair thinning treatment comes in a topical solution that is easy to use: Simply apply 1 milliliter directly to your scalp twice daily and massage it through your hair.” [from the product website https:\u002F\u002Fwww.lifecellskin.com\u002F]\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are intended for use as OTC hair grower drug products, among other intended uses.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, these drugs products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>As stated above, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are OTC hair grower drug products. According to 21 CFR 310.527(b), any OTC drug product that is labeled, represented, or promoted for external use as a hair grower or for hair loss prevention is regarded as a new drug within the meaning of section 201(p) of the FD&amp;C Act, for which an approved new drug application under section 505 of the FD&amp;C Act is required for marketing.\u003C\u002Fp>\u003Cp>“MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for these products.\u003C\u002Fp>\u003Cp>Accordingly, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of these products into interstate commerce violates section 301(d) of the FD&amp;C Act, 21 U.S.C.331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009569638 and ATTN: Christina Capacci-Daniel.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” also appear to be indicated to control seborrheic dermatitis. OTC control of seborrheic dermatitis drug products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use (M032). These products do not conform to the conditions set forth in this monograph. “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are labeled as both external use hair growth and control of seborrheic dermatitis drug products. These products cannot meet the requirement of M032 because hair growth claims go beyond the intended use claims permitted in M032. Additionally, minoxidil, is not a permitted active ingredient in M032. Although the Drug Facts Panels of these products do not specifically list this ingredient as an active ingredient, the website’s statements describing the pharmacological activity of the ingredient along with the prominence of this ingredient demonstrate that it is an “active ingredient” as defined in 21 CFR 201.66(b)(2) because it is intended to furnish pharmacological activity (under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-36\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Ijyahu Raphe Eze\n\nRecipient Title\n\nOwner\n\nAmWiner & Raphe Holdings, LLC dba rapheGenerics Corp\n\n802 East Walnut Street\n\nGarland, TX 75040\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-36\nJanuary 29, 2025\nDear Ms. Eze:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, AmWiner & Raphe Holdings LLC, FEI 3009569638, at 11601 Plano Road Suite 104, Dallas, Texas 75243, from June 20 to August 7, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). These violations are described in more detail below.\nWe reviewed your August 21, 2024 response to our Form FDA 483 in detail.\nCGMP Violations\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm manufactures topical over-the-counter (OTC) drug products, including drug products that contain the active ingredient minoxidil. You failed to establish adequate release testing procedures or specifications for your OTC drug products, and accordingly released batches of drug products for distribution without conducting adequate testing to confirm critical quality attributes.\nIn your response, you state that your finished product testing will be performed by a contract laboratory. Your response is inadequate. You did not describe how you will ensure that your finished products meet appropriate quality standards prior to release. You also did not consider a detailed risk assessment addressing the potential effects of releasing drug product to the market without established specifications to ensure their identity, strength, quality, and purity.\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\nYour firm failed to complete equipment and process performance qualification (PPQ) prior to releasing your OTC drug products. Likewise, you lacked appropriate documentation, qualification, maintenance, and monitoring of your purified water system, which is used in the manufacture of your OTC drug products.\nIn your response, you state that procedures have been established to monitor and validate the performance of your manufacturing processes including qualifying all manufacturing equipment. You also commit to testing your purified water before it used in any manufacturing process.\nYour response is inadequate as you did not provide sufficient information (such as validation protocols, reports, or timelines) to establish that your equipment and processes are adequately qualified and validated. Further, information, such as sampling procedures, testing procedures, method validation, or routine monitoring results, were not provided to support that your purified water system is adequately monitored and maintained.\nIn response to this letter, provide:\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for PPQ and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive remediation plan for the design, control, and maintenance of the water system.\no A purified water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your purified water system. Ensure that the total count limits for your purified water are appropriately stringent in view of the intended use of each of the products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets Purified Water, USP monograph specifications and appropriate microbial limits.\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to adequately test your incoming components, including propylene glycol and active ingredients such as minoxidil, for identity before using them in the manufacture of your OTC drug products. Additionally, you relied on your suppliers’ certificates of analysis (COAs) without establishing the reliability of each of your suppliers’ analyses at appropriate intervals.\nPropylene Glycol\nYou failed to adequately test each shipment of each lot of propylene glycol for identity, components at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. Identity testing for glycerin, propylene glycol, and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug product.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you state that “full compendial” testing of raw materials will be performed by a contract laboratory. You also state that propylene glycol will be tested for DEG impurities before use in manufacturing, and that your firm will no longer depend on the manufacturer's COA for propylene glycol and minoxidil. Your response is inadequate. You did not provide a detailed plan for how components will be tested, including test methods and review of compendial requirements, or a timeline for implementing the corrective actions proposed. Additionally, you did not describe how you plan to establish the reliability of the test results on your suppliers’ COAs at appropriate intervals. Further, you did not consider testing retains of raw materials or a retrospective review of previously distributed OTC drug products.\nWithout adequate testing, you do not have appropriate assurance that components conform to appropriate specifications prior to use in the drug products you manufacture.\nIn response to this letter, provide:\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product lots for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, propylene glycol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical and microbiology quality control specifications you use to test each incoming lot of each incoming lot of components, including, high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nUnapproved New Drug Violations\n“MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH”\n“HAIR REGROWTH TREATMENT EXTRA STRENGTH” [from the product label]\n“Uses · Relieves scalp itching, irritation, redness, flaking and scaling due to seborrheic dermatitis · Helps eliminate recurrence of seborrheic dermatitis” [from the product label]\n“Help hair loss and regrow fuller hair with LifeCell Extra Strength Hair Regrowth Treatment. This fast-working hair loss treatment is clinically proven to regrow up to 25% more hair. Unlike hair loss shampoos and hair thickening products that temporarily plump hair from the outside, LifeCell penetrates the scalp to reactivate shrunken hair follicles. The Minoxidil formula works to boost hair follicle activity and hair protein production, allowing for regrowth of hair. This hair thinning treatment comes in a topical solution that is easy to use: Simply apply 1 milliliter directly to your scalp twice daily and massage it through your hair.” [from the product website https:\u002F\u002Fwww.lifecellskin.com\u002F]\n“WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT”\n“HAIR REGROWTH TREATMENT” [from the product label]\n“Reactivates Hair Follicles To Stimulate Regrowth” [from the product label]\n“Uses · Relieves scalp itching, irritation, redness, flaking and scaling due to seborrheic dermatitis · Helps eliminate recurrence of seborrheic dermatitis” [from the product label]\n“Help hair loss and regrow fuller hair with LifeCell Extra Strength Hair Regrowth Treatment. This fast-working hair loss treatment is clinically proven to regrow up to 25% more hair. Unlike hair loss shampoos and hair thickening products that temporarily plump hair from the outside, LifeCell penetrates the scalp to reactivate shrunken hair follicles. The Minoxidil formula works to boost hair follicle activity and hair protein production, allowing for regrowth of hair. This hair thinning treatment comes in a topical solution that is easy to use: Simply apply 1 milliliter directly to your scalp twice daily and massage it through your hair.” [from the product website https:\u002F\u002Fwww.lifecellskin.com\u002F]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are intended for use as OTC hair grower drug products, among other intended uses.2 As described below, these drugs products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nAs stated above, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are OTC hair grower drug products. According to 21 CFR 310.527(b), any OTC drug product that is labeled, represented, or promoted for external use as a hair grower or for hair loss prevention is regarded as a new drug within the meaning of section 201(p) of the FD&C Act, for which an approved new drug application under section 505 of the FD&C Act is required for marketing.\n“MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products.\nAccordingly, “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of these products into interstate commerce violates section 301(d) of the FD&C Act, 21 U.S.C.331(d).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009569638 and ATTN: Christina Capacci-Daniel.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n2 We note that “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” also appear to be indicated to control seborrheic dermatitis. OTC control of seborrheic dermatitis drug products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use (M032). These products do not conform to the conditions set forth in this monograph. “MEN’S LIFECELL HAIR RESTORATION SOLUTION HAIR REGROWTH TREATMENT EXTRA STRENGTH” and “WOMENS LIFECELL 2% MINOXIDIL TOPICAL SOLUTION USP HAIR REGROWTH TREATMENT” are labeled as both external use hair growth and control of seborrheic dermatitis drug products. These products cannot meet the requirement of M032 because hair growth claims go beyond the intended use claims permitted in M032. Additionally, minoxidil, is not a permitted active ingredient in M032. Although the Drug Facts Panels of these products do not specifically list this ingredient as an active ingredient, the website’s statements describing the pharmacological activity of the ingredient along with the prominence of this ingredient demonstrate that it is an “active ingredient” as defined in 21 CFR 201.66(b)(2) because it is intended to furnish pharmacological activity (under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body).","AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp","amwiner-raphe-holdings-llc-dba-raphegenerics-corp-698782-01292025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famwiner-raphe-holdings-llc-dba-raphegenerics-corp-698782-01292025","2026-10-26T08:07:55.688833+00:00","2025-02-18","698782","Ms. Ijyahu Raphe Eze","2026-08-19T17:01:20.013+00:00","320-25-36","2025-01-29",{"id":290,"raw":291,"subject":39,"body_html":295,"body_text":296,"firm_name":297,"letter_id":298,"created_at":44,"fei_number":20,"letter_url":299,"updated_at":300,"action_type":23,"case_status":24,"posted_date":301,"marcs_cms_no":302,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":303,"body_fetched_at":304,"delivery_method":52,"recipient_title":20,"reference_number":20,"action_taken_date":301,"medical_device_id":20,"response_letter_date":20},2061,[292,293,294,38,39,13,13,13],"\u003Ctime datetime=\"2023-06-08T19:00:00Z\">06\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-08T04:00:00Z\">06\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flb-vision-holdings-inc-dba-vapermate-206-llc-658051-06082023\">LB Vision Holdings, Inc. d\u002Fb\u002Fa VaperMate #206, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Linda Botta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>LB Vision Holdings, Inc. d\u002Fb\u002Fa VaperMate #206, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3833 South Nova Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Orange\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32127\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:portorange.fl@vapormate.com\"> portorange.fl@vapormate.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Botta:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that LB Vision Holdings, Inc. d\u002Fb\u002Fa VaperMate #206, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Green Apple.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300841, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc: joshv@vapermate.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nLinda Botta\n\nRecipient Title\n\nOwner\n\nLB Vision Holdings, Inc. d\u002Fb\u002Fa VaperMate #206, LLC\n\n3833 South Nova Road\n\nPort Orange, FL 32127\n\nUnited States\n\nportorange.fl@vapormate.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 8, 2023\n\nWARNING LETTER\n\nDear Ms. Botta:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that LB Vision Holdings, Inc. d\u002Fb\u002Fa VaperMate #206, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Green Apple.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300841, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc: joshv@vapermate.com","LB Vision Holdings, Inc. d\u002Fb\u002Fa VaperMate #206, LLC","lb-vision-holdings-inc-dba-vapermate-206-llc-658051-06082023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flb-vision-holdings-inc-dba-vapermate-206-llc-658051-06082023","2026-10-26T08:09:12.790002+00:00","2023-06-08","658051","Linda Botta","2026-08-20T01:03:41.384+00:00",{"id":306,"raw":307,"subject":39,"body_html":311,"body_text":312,"firm_name":313,"letter_id":314,"created_at":67,"fei_number":20,"letter_url":315,"updated_at":316,"action_type":23,"case_status":24,"posted_date":317,"marcs_cms_no":318,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":319,"body_fetched_at":320,"delivery_method":52,"recipient_title":20,"reference_number":321,"action_taken_date":322,"medical_device_id":20,"response_letter_date":20},1256,[308,309,310,38,39,13,13,13],"\u003Ctime datetime=\"2024-09-13T13:00:00Z\">09\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-12T04:00:00Z\">09\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbeard-management-inc-dba-beard-vape-co-dba-lucky-bar-holdings-dba-fifty-bar-692147-09122024\">Beard Management Inc. d\u002Fb\u002Fa Beard Vape Co. d\u002Fb\u002Fa Lucky Bar Holdings, d\u002Fb\u002Fa Fifty Bar\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402205\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brady Bates, Casey Bates\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Colbey Pfund and Josey Orr\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Beard Management Inc. d\u002Fb\u002Fa Beard Vape Co. d\u002Fb\u002Fa Lucky Bar Holdings, d\u002Fb\u002Fa Fifty Bar\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4500 S. Pleasant Valley Rd., Ste. 105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78744\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@bearddistro.com\"> info@bearddistro.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 12, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Brady Bates, Casey Bates, Colbey Pfund, and Josey Orr:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthefiftybar.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Fifty Bar 6500 Puff Rechargeable Disposable Mint, Fifty Bar 6500 Puff Rechargeable Disposable Vanilla Custard, and Fifty Bar 6500 Puff Rechargeable Disposable Pacific Cooler.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402205, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>John E. Verbeten\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Beard Vape Co., LLC\u003Cbr>\n10957 Venice Blvd.\u003Cbr>\nLos Angeles, CA 90034\u003C\u002Fp>\n\n\u003Cp>Beard Vape Co., Inc.\u003Cbr>\n1046 Prince Dr., Unit 112\u003Cbr>\nMarina Del Rey, CA 90292\u003C\u002Fp>\n\n\u003Cp>Beard Management Inc.\u003Cbr>\nAttn: Susan Peckham\u003Cbr>\n3900 Toro Canyon Road\u003Cbr>\nAustin, TX 78746\u003C\u002Fp>\n\n\u003Cp>Lucky Bar Holdings LLC\u003Cbr>\n206 E 9th St Ste 1300\u003Cbr>\nAustin, TX 78701\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402205\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nBrady Bates, Casey Bates\n\nRecipient Title\n\nColbey Pfund and Josey Orr\n\nBeard Management Inc. d\u002Fb\u002Fa Beard Vape Co. d\u002Fb\u002Fa Lucky Bar Holdings, d\u002Fb\u002Fa Fifty Bar\n\n4500 S. Pleasant Valley Rd., Ste. 105\n\nAustin, TX 78744\n\nUnited States\n\ninfo@bearddistro.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 12, 2024\n\nWARNING LETTER\n\nDear Brady Bates, Casey Bates, Colbey Pfund, and Josey Orr:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthefiftybar.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Fifty Bar 6500 Puff Rechargeable Disposable Mint, Fifty Bar 6500 Puff Rechargeable Disposable Vanilla Custard, and Fifty Bar 6500 Puff Rechargeable Disposable Pacific Cooler.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402205, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJohn E. Verbeten\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nBeard Vape Co., LLC\n\n10957 Venice Blvd.\n\nLos Angeles, CA 90034\n\nBeard Vape Co., Inc.\n\n1046 Prince Dr., Unit 112\n\nMarina Del Rey, CA 90292\n\nBeard Management Inc.\n\nAttn: Susan Peckham\n\n3900 Toro Canyon Road\n\nAustin, TX 78746\n\nLucky Bar Holdings LLC\n\n206 E 9th St Ste 1300\n\nAustin, TX 78701\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com","Beard Management Inc. d\u002Fb\u002Fa Beard Vape Co. d\u002Fb\u002Fa Lucky Bar Holdings, d\u002Fb\u002Fa Fifty Bar","beard-management-inc-dba-beard-vape-co-dba-lucky-bar-holdings-dba-fifty-bar-692147-09122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbeard-management-inc-dba-beard-vape-co-dba-lucky-bar-holdings-dba-fifty-bar-692147-09122024","2026-10-26T08:08:02.332303+00:00","2024-09-13","692147","Brady Bates, Casey Bates","2026-08-19T23:48:12.44+00:00","RW2402205","2024-09-12",{"id":324,"raw":325,"subject":330,"body_html":331,"body_text":332,"firm_name":333,"letter_id":334,"created_at":44,"fei_number":20,"letter_url":335,"updated_at":336,"action_type":23,"case_status":24,"posted_date":337,"marcs_cms_no":20,"product_type":338,"closeout_date":20,"issuing_office":11,"recipient_name":339,"body_fetched_at":340,"delivery_method":341,"recipient_title":20,"reference_number":20,"action_taken_date":342,"medical_device_id":20,"response_letter_date":20},2294,[326,327,328,11,329,13,13,13],"\u003Ctime datetime=\"2022-12-13T14:20:00Z\">12\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-05T05:00:00Z\">12\u002F05\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057\">Thriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated Human Foods\u003Cbr \u002F>\r\n","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated Human Foods","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Haynes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Thriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2614 Andjon Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@thriftmasterholdings.com\"> admin@thriftmasterholdings.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 5, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: # 641057\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Steven Haynes:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at www.cedarcreekdistributors.com, www.thriftmasterholdings.com, and https:\u002F\u002Fapelindx.com in November 2022 and has determined that you take orders there for various products, which you represent as containing cannabidiol (CBD).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> We have also reviewed your social media websites at www.instagram.com\u002Fthriftmasterholdings and www.facebook.com\u002Fthriftmasterholdings, which are accessible from your website www.thriftmasterholdings.com, where consumers can purchase your products. The claims on your websites and social media accounts establish that your products, “ApelinDx metered dose inhaler,” “Maia CBD Tincture Inhaler,” “Maia CBD Oil,” “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” “Maia Gummies,” and “CBD Pill” (hereinafter referred to as “your CBD products”), are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1).\u003C\u002Fp>\n\n\u003Cp>FDA has also determined that your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” food products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products into interstate commerce under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll). Consumers may confuse these products with traditional foods; therefore, with these products there is a risk of unintended consumption of CBD.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find specific information about how FDA regulates cannabis-derived products at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We also observed that your website, www.thriftmasterholdings.com, and social media websites make claims that your CBD products may be intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Furthermore, your “ApelinDx metered dose inhaler” and “Maia CBD Tincture Inhaler” products are intended to deliver CBD through oral inhalation. These products are particularly concerning to the agency because the ingredients and potential impurities in oral inhalation sprays may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways. Inhalation products that are intended to act locally in the respiratory system also may be absorbed and exert undesirable systemic effects, such as increased heart rate or elevated blood pressure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your websites and social media websites, your CBD products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your websites and social media websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your “About Us” webpage https:\u002F\u002Fcedarcreekdistributors.com\u002Fabout-us\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD is FDA approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous Sclerosis Complex.”\u003C\u002Fli>\n\t\u003Cli>“As of 2020, there are various clinical studies underway hoping to determine CBD’s long-thought potential to assist with a variety of physical and mental health ailments, including pain, mood disorders and respiratory problems.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “We’re in the News” hyperlink https:\u002F\u002Fthriftmasterholdings.com\u002Fwp-content\u002Fuploads\u002F2021\u002F07\u002FUSA-today-AD-compressed-7.15.21.pdf accessed through your website www.thriftmasterholdings.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD May Be Key to Reducing ARDS, the Leading Cause of COVID-19 Deaths”\u003C\u002Fli>\n\t\u003Cli>“Thriftmaster has been heavily involved in clinical studies, with a goal of proving CBD and CBC’s efficacy to improved conditions related to aliments such as . . . Alzheimer’s and Post Traumatic Stress Disorder.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “CBD Helps” hyperlink https:\u002F\u002Fwww.eurekalert.org\u002Fpub_releases\u002F2020-10\u002Fmcog-chr101620.php accessed through your website www.thriftmasterholdings.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD helps reduce lung damage from COVID by increasing levels of protective peptide”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Instagram social media website www.instagram.com\u002Fthriftmasterholdings:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>May 31, 2021 post – “Learn more about how ApelinDx™ supports ARDS and Alzheimer’s research (link in bio).”\u003C\u002Fli>\n\t\u003Cli>June 14, 2021 post – “TM Global Bioscience, LLC, a medically-focused division of ThriftMaster Global Holdings, announced that the patent-pending broad-spectrum CBD formulation in its ApelinDx™ metered dose inhaler may increase survival rates of COVID-19 patients.”\u003C\u002Fli>\n\t\u003Cli>June 21, 2021 post – “See our product being used in ‘a new research collaboration between the Dental College of Georgia and the Medical College of Georgia is investigating the affect [sic] CBD can have on reducing plaque in the brain of Alzheimer’s patients.’”\u003C\u002Fli>\n\t\u003Cli>June 30, 2021 post – “We are heading towards finding answers about the potential CBD has to make a change in the medical world . . . #apelindx #metereddoseinhaler #mdi #alzheimers #alzheimersawareness #dementia #dementiaawareness #cbd #cbdinhaler”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook social media website www.facebook.com\u002Fthriftmasterholdings:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>February 1, 2021 post – “Early studies suggest that CBD may be a useful tool in the fight against COVID-19.”\u003C\u002Fli>\n\t\u003Cli>February 4, 2021 post – “[A] study out of the Innovare Journal of Medical Sciences produced promising results regarding #cannibidiols [sic] potential to assist with cognitive illnesses, including #anxiety and #depression.”\u003C\u002Fli>\n\t\u003Cli>March 25, 2021 post – “‘Researchers discovered in this trial that in mice who have been genetically altered to show symptoms of Alzheimer’s, #CBD normalized levels and functions; improving brain cognition’.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your website https:\u002F\u002Fapelindx.com hyperlinks to a news report discussing the use of CBD to delay the progression of Alzheimer’s disease. The news report shows an image of a product that states “ApelinDx” on the label and appears to be a metered dose inhaler.\u003C\u002Fp>\n\n\u003Cp>Your CBD products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your CBD products are misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) Your CBD products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products. The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>301(ll) and Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are foods to which CBD has been added.\u003C\u002Fp>\n\n\u003Cp>However, you should be aware that it is a prohibited act under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>You should also be aware that, as defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>* * *\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your websites www.thriftmasterholdings.com and https:\u002F\u002Fapelindx.com redirect consumers to your website www.cedarcreekdistributors.com to purchase your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See \u003Cstrong>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome\u003C\u002Fstrong>). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSteven Haynes\n\nThriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC\n\n2614 Andjon Dr.\n\nDallas, TX 75220\n\nUnited States\n\nadmin@thriftmasterholdings.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nCenter for Food Safety and Applied Nutrition\n\nWARNING LETTER\n\nDecember 5, 2022\n\nRE: # 641057\n\nDear Steven Haynes:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at www.cedarcreekdistributors.com, www.thriftmasterholdings.com, and https:\u002F\u002Fapelindx.com in November 2022 and has determined that you take orders there for various products, which you represent as containing cannabidiol (CBD).1 We have also reviewed your social media websites at www.instagram.com\u002Fthriftmasterholdings and www.facebook.com\u002Fthriftmasterholdings, which are accessible from your website www.thriftmasterholdings.com, where consumers can purchase your products. The claims on your websites and social media accounts establish that your products, “ApelinDx metered dose inhaler,” “Maia CBD Tincture Inhaler,” “Maia CBD Oil,” “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” “Maia Gummies,” and “CBD Pill” (hereinafter referred to as “your CBD products”), are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).\n\nFDA has also determined that your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” food products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products into interstate commerce under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll). Consumers may confuse these products with traditional foods; therefore, with these products there is a risk of unintended consumption of CBD.\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nWe also observed that your website, www.thriftmasterholdings.com, and social media websites make claims that your CBD products may be intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.2 As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Furthermore, your “ApelinDx metered dose inhaler” and “Maia CBD Tincture Inhaler” products are intended to deliver CBD through oral inhalation. These products are particularly concerning to the agency because the ingredients and potential impurities in oral inhalation sprays may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways. Inhalation products that are intended to act locally in the respiratory system also may be absorbed and exert undesirable systemic effects, such as increased heart rate or elevated blood pressure.\n\nUnapproved New Drugs\n\nBased on a review of your websites and social media websites, your CBD products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your websites and social media websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nOn your “About Us” webpage https:\u002F\u002Fcedarcreekdistributors.com\u002Fabout-us\u002F:\n\n“CBD is FDA approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous Sclerosis Complex.”\n\n“As of 2020, there are various clinical studies underway hoping to determine CBD’s long-thought potential to assist with a variety of physical and mental health ailments, including pain, mood disorders and respiratory problems.”\n\nOn your “We’re in the News” hyperlink https:\u002F\u002Fthriftmasterholdings.com\u002Fwp-content\u002Fuploads\u002F2021\u002F07\u002FUSA-today-AD-compressed-7.15.21.pdf accessed through your website www.thriftmasterholdings.com:\n\n“CBD May Be Key to Reducing ARDS, the Leading Cause of COVID-19 Deaths”\n\n“Thriftmaster has been heavily involved in clinical studies, with a goal of proving CBD and CBC’s efficacy to improved conditions related to aliments such as . . . Alzheimer’s and Post Traumatic Stress Disorder.”\n\nOn your “CBD Helps” hyperlink https:\u002F\u002Fwww.eurekalert.org\u002Fpub_releases\u002F2020-10\u002Fmcog-chr101620.php accessed through your website www.thriftmasterholdings.com:\n\n“CBD helps reduce lung damage from COVID by increasing levels of protective peptide”\n\nOn your Instagram social media website www.instagram.com\u002Fthriftmasterholdings:\n\nMay 31, 2021 post – “Learn more about how ApelinDx™ supports ARDS and Alzheimer’s research (link in bio).”\n\nJune 14, 2021 post – “TM Global Bioscience, LLC, a medically-focused division of ThriftMaster Global Holdings, announced that the patent-pending broad-spectrum CBD formulation in its ApelinDx™ metered dose inhaler may increase survival rates of COVID-19 patients.”\n\nJune 21, 2021 post – “See our product being used in ‘a new research collaboration between the Dental College of Georgia and the Medical College of Georgia is investigating the affect [sic] CBD can have on reducing plaque in the brain of Alzheimer’s patients.’”\n\nJune 30, 2021 post – “We are heading towards finding answers about the potential CBD has to make a change in the medical world . . . #apelindx #metereddoseinhaler #mdi #alzheimers #alzheimersawareness #dementia #dementiaawareness #cbd #cbdinhaler”\n\nOn your Facebook social media website www.facebook.com\u002Fthriftmasterholdings:\n\nFebruary 1, 2021 post – “Early studies suggest that CBD may be a useful tool in the fight against COVID-19.”\n\nFebruary 4, 2021 post – “[A] study out of the Innovare Journal of Medical Sciences produced promising results regarding #cannibidiols [sic] potential to assist with cognitive illnesses, including #anxiety and #depression.”\n\nMarch 25, 2021 post – “‘Researchers discovered in this trial that in mice who have been genetically altered to show symptoms of Alzheimer’s, #CBD normalized levels and functions; improving brain cognition’.”\n\nAdditionally, your website https:\u002F\u002Fapelindx.com hyperlinks to a news report discussing the use of CBD to delay the progression of Alzheimer’s disease. The news report shows an image of a product that states “ApelinDx” on the label and appears to be a metered dose inhaler.\n\nYour CBD products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Drugs\n\nYour CBD products are misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) Your CBD products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use because no FDA-approved applications are in effect for these products. The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n301(ll) and Adulterated Human Foods\n\nAccording to your product labeling, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are foods to which CBD has been added.\n\nHowever, you should be aware that it is a prohibited act under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.3 There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nYou should also be aware that, as defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.4\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your “Maia Dried Mango Slices,” “Maia Dried Pineapple Chunks,” and “Maia Gummies” products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n____________________\n\n1 Your websites www.thriftmasterholdings.com and https:\u002F\u002Fapelindx.com redirect consumers to your website www.cedarcreekdistributors.com to purchase your products.\n\n2 On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n3 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n4 Under section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.","Thriftmaster Texas, LLC. d\u002Fb\u002Fa ThriftMaster Global Holdings, Inc. and TM Global Biosciences, LLC","thriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthriftmaster-texas-llc-dba-thriftmaster-global-holdings-inc-and-tm-global-biosciences-llc-641057","2026-10-26T08:10:11.866518+00:00","2022-12-13","DrugsFood & Beverages","Steven Haynes","2026-08-20T01:22:50.74+00:00","Via Email","2022-12-05",17,{"510k":345,"classification":346,"enforcement":347,"event":348,"event_backfill":349,"pma":350,"warning_letter":351},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]